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A B S T R A C T
Background
This is an update of the original review published in the Cochrane Database of Systematic Reviews Issue 10, 2015.
Invasive aspergillosis (IA) is themost common life-threatening opportunistic invasive mould infection in immunocompromised people.
Early diagnosis of IA and prompt administration of appropriate antifungal treatment are critical to the survival of people with IA.
Antifungal drugs can be given as prophylaxis or empirical therapy, instigated on the basis of a diagnostic strategy (the pre-emptive
approach) or for treating established disease. Consequently, there is an urgent need for research into both new diagnostic tools and
drug treatment strategies. Increasingly, newer methods such as polymerase chain reaction (PCR) to detect fungal nucleic acids are being
investigated.
Objectives
To provide an overall summary of the diagnostic accuracy of PCR-based tests on blood specimens for the diagnosis of IA in immuno-
compromised people.
Search methods
We searchedMEDLINE (1946 to June 2015) and Embase (1980 to June 2015). We also searched LILACS, DARE, Health Technology
Assessment, Web of Science and Scopus to June 2015. We checked the reference lists of all the studies identified by the above methods
and contacted relevant authors and researchers in the field. For this review update we updated electronic searches of the Cochrane
Central Register of Controlled Trials (CENTRAL; 2018, Issue 3) in the Cochrane Library; MEDLINE via Ovid (June 2015 to March
week 2 2018); and Embase via Ovid (June 2015 to 2018 week 12).
1Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Selection criteria
We included studies that: i) compared the results of blood PCR tests with the reference standard published by the EuropeanOrganisation
for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG); ii) reported data on false-positive, true-positive, false-
negative and true-negative results of the diagnostic tests under investigation separately; and iii) evaluated the test(s) prospectively in
cohorts of people from a relevant clinical population, defined as a group of individuals at high risk for invasive aspergillosis. Case-
control and retrospective studies were excluded from the analysis.
Data collection and analysis
Authors independently assessed quality and extracted data. For PCR assays, we evaluated the requirement for either one or two
consecutive samples to be positive for diagnostic accuracy. We investigated heterogeneity by subgroup analyses. We plotted estimates
of sensitivity and specificity from each study in receiver operating characteristics (ROC) space and constructed forest plots for visual
examination of variation in test accuracy. We performed meta-analyses using the bivariate model to produce summary estimates of
sensitivity and specificity.
Main results
We included 29 primary studies (18 from the original review and 11 from this update), corresponding to 34 data sets, published
between 2000 and 2018 in the meta-analyses, with a mean prevalence of proven or probable IA of 16.3 (median prevalence 11.1%
, range 2.5% to 57.1%). Most patients had received chemotherapy for haematological malignancy or had undergone hematopoietic
stem cell transplantation. Several PCR techniques were used among the included studies. The sensitivity and specificity of PCR for the
diagnosis of IA varied according to the interpretative criteria used to define a test as positive. The summary estimates of sensitivity and
specificity were 79.2% (95% confidence interval (CI) 71.0 to 85.5) and 79.6% (95% CI 69.9 to 86.6) for a single positive test result,
and 59.6% (95% CI 40.7 to 76.0) and 95.1% (95% CI 87.0 to 98.2) for two consecutive positive test results.
Authors’ conclusions
PCR shows moderate diagnostic accuracy when used as screening tests for IA in high-risk patient groups. Importantly the sensitivity
of the test confers a high negative predictive value (NPV) such that a negative test allows the diagnosis to be excluded. Consecutive
positives show good specificity in diagnosis of IA and could be used to trigger radiological and other investigations or for pre-emptive
therapy in the absence of specific radiological signs when the clinical suspicion of infection is high. When a single PCR positive test is
used as the diagnostic criterion for IA in a population of 100 people with a disease prevalence of 16.3% (overall mean prevalence), three
people with IA would be missed (sensitivity 79.2%, 20.8% false negatives), and 17 people would be unnecessarily treated or referred
for further tests (specificity of 79.6%, 21.4% false positives). If we use the two positive test requirement in a population with the same
disease prevalence, it would mean that nine IA people would be missed (sensitivity 59.6%, 40.4% false negatives) and four people
would be unnecessarily treated or referred for further tests (specificity of 95.1%, 4.9% false positives). Like galactomannan, PCR has
good NPV for excluding disease, but the low prevalence of disease limits the ability to rule in a diagnosis. As these biomarkers detect
different markers of disease, combining them is likely to prove more useful.
P L A I N L A N G U A G E S U M M A R Y
A new, non-invasive diagnostic blood test - polymerase chain reaction - for people at risk of an invasive mould infection
(aspergillosis)
Review question
We reviewed the evidence about the accuracy of polymerase chain reaction (PCR) tests for diagnosing invasive aspergillosis (IA) among
people with defective immune systems from medical treatment such as chemotherapy or following organ or bone marrow transplant.
Background
IA is a fungal disease caused by the widespread mould Aspergillus, with Aspergillus fumigatus being the most common species. Most
people breathe in Aspergillus spores every day without becoming ill. However people with weakened immune systems or lung diseases
are at a higher risk of developing respiratory problems of the lungs and sinuses due to Aspergillus, ranging from allergic complications to
IA, which is the most common life-threatening, invasive fungal infection of people whose immune systems are compromised. Without
antifungal treatment, most people with IA will die as a direct result of IA, so early diagnosis and prompt administration of appropriate
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antifungal treatment are both critical to the survival of these people. The ideal specimen for diagnosing IA would be lung tissue but
obtaining this carries a significant risk to the patient so there is a clear need for new, non-invasive methods such as PCR to demonstrate
the fungus’s presence in blood by detecting its nucleic acids.
Study characteristics
We conducted our most recent search for studies in March 2018 and combined with an earlier search selected 29 clinical studies
reporting the evaluation of PCR tests prospectively in cohorts of people at high risk of IA.
Study funding sources
None of the companies involved in the diagnosis of invasive fungal diseases funded any of the studies included in the review.
Quality of the evidence
Most studies were at low risk of bias and low concern regarding applicability. However, differences in the reference standard may have
contributed to differences we found in the distribution of cases as being classified as IA or not.
Key results
Several PCR techniques were used in the studies. Pooling the data from the studies showed that sensitivity and specificity of PCR for
the diagnosis of IA varied (from 59% to 79.2% and from 79% to 95.2%, respectively) depending on the interpretative criteria used to
define a test as positive. When used as a diagnostic criterion for IA in a population of 100 people with a disease prevalence of 16.3%
(overall mean prevalence), a single PCR positive test would have missed three people with the disease, and falsely classified 17 people as
having the disease, who would be treated unnecessarily or referred for further tests. A requirement of two positive tests as a diagnostic
criterion in a population with the same disease prevalence would miss nine people with the disease and falsely classify four people as
having the disease. These numbers should be interpreted with caution because the reference standard is based on the degree of certainty
of diagnosis and is rarely proven so cannot provide consistent assessment of cases as being IA or not.
Overall, PCR shows moderate diagnostic accuracy when used as a screening test for IA in high-risk patient groups. Importantly, when
the rate of sensitivity is low, the sensitivity of the tests means that a negative result allows the diagnosis to be excluded with confidence
except when the patient is receiving certain antifungal drugs. With the low prevalence of the disease, a high negative predictive value
such that a negative test allows the diagnosis to be excluded.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Review question: what is the diagnost ic accuracy of aspergillus PCR blood test for detect ion of invasive aspergillosis (IA)?
Patients/population: pat ients at risk of IA, including neutropenic cancer pat ients and HSCT or solid organ transplant recipients
Index test: PCR on blood specimens (whole blood or serum). We considered dif ferent DNA extract ion methods and PCR methods (e.g. nested, ELISA, qPCR)
Reference standard: EORTC/MSG criteria for invasive aspergillosis
Studies: cohort studies
Index Test: interpretat ive criteria
to def ine a test as posit ive
Ef fect (95%CI) No. of studies Mean prevalence
(range)
What do these results mean?
1 Single PCR specimen sensit ivity: 79.2% (71.0% to 85.
5%)
specif icity: 79.6% (69.9% to 86.
6%)
27 studies 16.3% (2.5% to 57.1%) With a prevalence of 16%, 16 out of 100 pat ients will develop IA.
Of these, 3 will be missed by a single PCR test (20.8%of 16); of
the 84 pat ients without IA, 17 will have a false posit ive result of
the PCR test; repeat ing the test will reduced signif icant ly rates
of false posit ive results
≥ 2 PCR specimens sensit ivity: 59.6% (40.7% to 76.
0%)
specif icity: 95.1% (87.0% to 98.
2%)
9 studies 16.3% (2.5% to 57.1%) With a prevalence of 16%, 16 out of 100 pat ients will develop IA.
Of these, 9 will be missed using the 2 posit ive PCR test (40.4%
of 16); of the 84 pat ients without IA, 4 will have a false posit ive
result of the PCR test
The PCR methods varied notably across studies. Several covariates (in part icular, the adopt ion of ant if ungal prophylaxis and
blinding to the reference test or index test) were found to substant ively af fect the measures of diagnost ic accuracy under
evaluat ion, mainly sensit ivity and specif icity.
CI: conf idence interval
IA: invasive aspergillosis
PCR: polymerase chain react ion
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B A C K G R O U N D
Target condition being diagnosed
Invasive aspergillosis (IA) is a disease resulting from opportunistic
fungal infection and mainly affects immunocompromised hosts,
particularly neutropenic patients such as those undergoing can-
cer treatment and hematopoietic stem cell transplantation (HCT)
and solid organ transplant recipients (Flückiger 2006;Marr 2002).
The highest incidence (10% to 20%) and mortality rates (60%
to 90%) of IA have been reported following allogeneic HCT and
heart, lung or heart/lung transplantation. The principal reason for
such people developing IA is that the underlying disease and its
subsequent treatment with chemotherapy induces bone marrow
failure resulting in profound leucopenia and impaired innate and
cell-mediated immunity. The leucopenia is marked by a lack of
functioning polymorphonuclear leucocytes, resulting in the pa-
tient lacking the phagocytic white blood cells needed to fight in-
fections, including aspergillosis. Innate immunity is further im-
paired by iatrogenic damage to the local defences of the oral cavity,
gastrointestinal tract and respiratory tract. Damage to the respira-
tory tract is poorly understood but hampers effective clearance of
fungal spores, especially those of Aspergillus fumigatus which are
ubiquitous in the environment, readily airborne and small enough
to lodge in the alveolar spaces. The lack of local and systemic im-
mune defences means that any spores that germinate can infect
lung tissue and progress to a full-blown infection. The disease that
follows is characterised by invasion of the capillaries (angioinva-
sion) which can lead to further dissemination to other parts of the
lung and indeed other organs, particularly the brain.
Early diagnosis of IA and prompt administration of appropriate
antifungal treatment have been recognised as crucial to the survival
of people with IA (Marr 2002;Walsh 2008). Antifungal drugs can
be given for prevention of infection (prophylaxis), treatment of
unexplained fever (empirical therapy), treatment of non-specific
clinical features or mycological evidence (pre-emptive therapy)
and treatment of possible, probable and proven invasive fungal
disease (IFD) (directed therapy). Clearly, the earlier that treatment
is started the better the outcome. Consequently there is an urgent
need for new diagnostic tools to detect infection before disease
becomes manifest, thereby allowing effective treatment strategies
to be developed. The polymerase chain reaction (PCR) is becom-
ing increasingly popular (Arvanitis 2014; Donnelly 2006; Hope
2005; Mengoli 2009; Tuon 2007; White 2015). However it was
not considered robust enough to be included in the international
consensus definitions of the European Organisation for Research
and Treatment of Cancer/Mycoses StudyGroup (EORTC/MSG);
(Ascioglou 2002; De Pauw 2008).
The prevalence of IA varies from 1 in 100 to about 1 in 6 depend-
ing upon the level of compromised immunity, the environmental
exposure and preventative measures taken, which can include pro-
tected isolation with filtered air and antifungal prophylaxis. The
outcome depends upon the extent of infection, whether diagnosis
is made and treatment with an effective drug is initiated early;
and, importantly, whether or not an individual’s immune system
begins to recover (Marr 2002; Walsh 2008).
Demonstration of fungi in diseased tissue is still required for a
proven diagnosis of IFD. Unlike other infectious diseases, direct
demonstration of Aspergillus infection is rarely possible by culture
of sterile body fluids, and obtaining tissue from a live patient is
seldom feasible because of the risks posed to the patient.by biopsy.
Recently, advances have been made on several fronts. The
EORTC/MSG’s published definitions of invasive fungal disease
(IFD) allow for degrees of certainty of diagnosis: possible, proba-
ble and proven (Ascioglou 2002; De Pauw 2008). Definitions of
invasive fungal infection were devised in 2002 and revised in 2008
to focus on fungal disease (Table 1). These are based on host fac-
tors, radiological features and mycological evidence. Probable and
possible cases have to satisfy the same host and radiological criteria
and they are only distinguished by the presence or absence of my-
cological evidence. Biomarkers have potential to detect infection
before development of overt disease, allowing treatment to be ini-
tiated at an earlier stage. These definitions were onlymade possible
by other contemporaneous developments in the field. Computer-
assisted tomography (CT scan) became more widely available, al-
lowing lesions consistent with pulmonary IA to be detected at an
early stage of disease. This offered the possibility of performing
bronchoscopy to obtain bronchoalveolar fluid in which the fun-
gus could be detected by microscopy and culture as well as galac-
tomannan (GM). However the technique is not without risk and
cannot always be performed when required. By contrast, blood
is readily available which opens up the possibility of looking for
fungi in an indirect fashion by detecting fungal cell components
including the galactomannan of the cell wall of Aspergillus species
(Leeflang 2008).
The EORTC/MSG definitions help integrate all the clinical and
laboratory information available. Combining of host factor (such
as neutropenia) with clinical features (such as pulmonary nodules)
and mycological evidence (such as detection of GM) allows a high
level of certainty of diagnosis to be assigned. These definitions have
been adopted widely by regulatory agencies, such as the European
Medicines Agency and the US Food andDrug Administration, for
evaluating antifungal drug products and diagnostic tests, as well as
by the scientific and medical community at large for investigating
epidemiology and auditing antifungal stewardship.
Whilst the range of potential drugs currently available allows pro-
phylaxis, pre-emptive therapy, as well as directed therapy for pos-
sible, probable and proven IFD, the ability to identify ’who needs
treatment, when, and with what’ is sufficiently unreliable that
many physicians continue to treat empirically. Not only does this
lead to unnecessary costs but it is also not clear how many people
are helped or harmed by this approach. There are circumstances
when a host factor is present (for instance receipt of an allogeneic
hematopoietic stem cell transplant (HSCT)) and mycological ev-
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idence exists (such as Aspergillus being recovered from pulmonary
secretions) without evidence of active disease. This may represent
infection before disease becomes manifest and provides the oppor-
tunity for therapy to pre-empt disease. Consequently there is an
urgent need for new diagnostic tools and an assessment of their
utility in the clinic. Biomarkers have the potential to detect infec-
tion before development of overt disease, allowing treatment to be
initiated at an earlier stage.
Index test(s)
There are few direct diagnostic tests and those that are available
are limited by the difficulties in obtaining tissue specimens to al-
low culture, microscopy and histology (Chamilos 2006). Blood
in its various forms - whole blood, plasma and serum - is readily
available, but only tests for antigens such as GM and beta-D-glu-
can have been deemed acceptable to support a diagnosis (Leeflang
2008; Pfeiffer 2006; Senn 2008). In neutropenic patients, pul-
monary abnormalities consistent with invasive aspergillosis, such
as nodules, often surrounded by a ’halo sign’, can be detected using
high-resolution computed tomography (Greene 2007). However,
the ’halo sign’ is transient and only detectable during early invasive
aspergillosis, after which radiological signs become non-specific or
appear too late to be therapeutically useful (Caillot 2001). Radio-
logical signs also herald established disease so the opportunity to
intervene early has been lost.
Molecular methods, such as the PCR, have been investigated in
order to improve the diagnosis of IA (Donnelly 2006; Mengoli
2009; White 2010; White 2015). PCR can amplify a single or a
few copies of target DNA allowing target detection with great sen-
sitivity and specificity. Moreover it can be quantitative, using the
procedural variant called real-time PCR (qPCR). The sensitivity
is based on the enormous potential for exponential amplification
of the DNA target (the ’amplicon’) due to repeated cycles of the
polymerase reaction, where every cycle doubles the quantity of am-
plicon. Real-time PCR continuously monitors the amplification
of target DNA at every cycle. The threshold cycle number (pre-
ferred term Cq) is when the amplicon becomes detectable above
the background level, as an exponentially increasing signal, and is
proportional to the amount of starting DNA in the reaction. A
high initial DNA concentration will require fewer cycles to reach
the threshold and has an earlier Cq value. The specificity of PCR
resides in the DNA oligonucleotides used as primers, allowing the
terminally stable variant of the enzyme DNA polymerase to initi-
ate sequence duplication. These primers join to the DNA target
(’annealing’) in a very stringent way, allowing only minimal misfit
possibility. Moreover, in quantitative real time PCR (q-RT-PCR),
the use of reporter probes, hydrolysis probes or molecular beacons
that bind to the central part of the target sequence increase the
assay’s specificity.
PCR has an enormous potential for diagnosing infectious dis-
eases, particularly where traditional culture methods are less effec-
tive. The fungal genus Aspergillus is a good example of this kind
of approach. The recovery of Aspergillus from blood cultures is
rarely achieved even in overwhelming infection. PCR-based tests
on blood specimens have gained popularity as the platforms be-
come more automated and extraction methods and targets be-
come commercially available (White 2010). However, its exclu-
sion from the EORTC/MSG definitions led to the establishment
of the European Aspergillus PCR Initiative (EAPCRI), which is a
working group of the International Society of Human and Animal
Mycology (ISHAM). The EAPCRI has published various studies
describing the critical stages in DNA isolation from blood samples
(White 2010), and on the critical characteristics of a standardized
Aspergillus PCR assay. These studies, allied to the standardization
of qPCR assays described in the MIQE (minimum information
for publication of quantitative real-time PCR experiments) guide-
lines, have helped pave the way for reliable and robust PCR as-
says for the diagnosis of IA in the clinical setting (Bustin 2009).
Progress in the standardization of methodology enabled the de-
velopment of commercially available Aspergillus PCR assays in the
last few years (Rath 2018).
Clinical pathway
As stated above, many physicians still opt for starting antifun-
gal treatment empirically because of diagnostic uncertainty. This
approach can lead to unnecessary treatment, which incurs extra
costs, and may be harmful to some people. Diagnostic tests can
be used to establish (i.e. rule in or rule out) disease. This is partic-
ularly useful for people at risk of IA where a highly sensitive test
can deliver a high negative predictive value for disease, allowing
empirical therapy to be safely withheld even on the basis of a single
test result. Conversely, a high positive predictive value is required
to rule in the diagnosis. The use of PCR as a screening tool dif-
fers fundamentally from its use as confirmation of the diagnosis.
Therefore, if prevalence is low (i.e. < 10%), IA can be ruled out
during the risk period for as long as any single PCR test result is
negative, and there are no clinical signs of disease. Conversely, two
or more PCR positive test results could be used for mycological
confirmation of clinically suspected disease, also allowing a case of
possible IA to be upgraded to probable IA.
Clinical pathways of managing patients can vary according to the
risk of IA. Patients at high risk can be screened using GM, PCR (or
both), with positive test results being used to trigger an intensive
diagnostic workup with CT scanning and bronchoalveolar lavage
(BAL) to determine disease (diagnostic driven) or to initiate anti-
fungal treatment to prevent development of disease (pre-emptive).
Screening may occur throughout the period of risk or only when
people develop fever. Alternatively, patients may be tested in the
presence of symptoms suggestive of disease to confirm diagnosis.
6Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rationale
There is no single assay that has been validated for the early diag-
nosis of IA. Non-culture-based methods such as serial GM ELISA
screening hold most promise in establishing early diagnosis and
may result in improved outcomes, but clinical utility has not been
fully established. Moreover, newer methods such as PCR are being
investigated (Donnelly 2006;White 2015). Aswith any diagnostic
test, the utility of PCR as either a screening tool or a confirmatory
test will depend on the prevalence of disease in the population in
which it is used. The use of prophylactic or empirical antifungal
agents, availability of protective environments and other diagnos-
tic tests will all influence how the test is used in clinical practice. It
is not the aim of this present analysis to establish clinical outcomes
but rather to evaluate diagnostic accuracy so that rational use of
PCR testing can be applied to different populations.
O B J E C T I V E S
To provide an overall summary of the diagnostic accuracy of PCR-
based tests on blood specimens for the diagnosis of IA in immuno-
compromised people.
Secondary objectives
When studies included in the analysis also compared the diagnostic
performance of PCR techniques and the GM ELISA assay, we
comparatively evaluated the diagnostic performance of PCR-based
tests and GM ELISA assays. However, since the objective of this
review is not to identify all studies dealing with GM ELISA assays
and IA, only those within the study comparison were included in
the review.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies using PCR techniques on blood specimens
for analysis if they:
• compared the results of PCR tests with the diagnosis made
following the published case definition criteria for invasive fungal
disease proposed by the EORTC/MSG; or, for studies published
before the publication of these criteria in 2002, used comparable
criteria as a reference standard (Ascioglou 2002; De Pauw 2008);
• reported data on false-positive, true-positive, false-negative
and true-negative results of the diagnostic tests under
investigation separately; and
• evaluated the tests prospectively in a cohort of people from
a relevant clinical population, defined as a group of individuals at
high risk of IA.
We classified studies, on the basis of the samplingmethod, as being
consecutive or non-consecutive. We regarded studies evaluating
specimens from a group of people known to have aspergillosis,
and from a separate group of subjects without evidence of disease,
as case-control studies (Lijmer 1999). We included these studies
in the systematic review but excluded them from the quantitative
analysis.
Aspergillus contamination and false positive PCR resultswith bron-
choalveolar lavage (BAL) and sputum samples can follow inhala-
tion of airborne spores or colonization of the lung (Lewis 2006).
Moreover, BAL is an invasive procedure performed only to con-
firm the aetiology in a subset of cases that already meet the clin-
ical definitions of IA. Thus, to avoid bias related to the patient
selection and specimen type, we analysed only studies evaluating
PCR on blood (whole blood, serum, and plasma), with exclusion
of studies that analyse the accuracy of PCR tests on BAL only.
Participants
Patients at risk of IA, including neutropenic cancer patients and
hematopoietic stem cell transplant (HSCT) or solid organ trans-
plant recipients.
Index tests
PCR methods on blood specimens (whole blood or serum). We
considered different DNA extraction methods and PCR methods
(e.g. nested, ELISA, qPCR).
Target conditions
The target condition of this review is IA (systemic aspergillosis).
Reference standards
Definitions for invasive fungal disease were first published in 2002
by the EORTC/MSG (Ascioglou 2002); theywere revised in 2008
(De Pauw 2008; Table 1). These were used as a reference standard
and comparable criteria were used for studies published before the
publication of the definitions in 2002. The EORTC/MSG defi-
nitions divide the patient population into four categories: people
with proven IA, people with probable IA, people with possible IA,
and people without IA. In accordance with the previous Aspergillus
review on Aspergillus GM detection (Leeflang 2008), sensitivity
and specificity were assessed in each study considering the proven
and probable cases of IA as having the disease, and the cases of
possible IA and no IA as not having the disease.
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Search methods for identification of studies
The search strategies for MEDLINE, Embase and CENTRAL are
listed in Appendix 1.
Electronic searches
Weupdated searches on the following electronic databases to iden-
tify reports of relevant studies for the review update.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, Issue 3), in the Cochrane Library;
• MEDLINE via Ovid (June 2015 to March week 2 2018);
• Embase via Ovid (June 2015 to 2018, week 12);
• LILACS (June 2015 to September 2018);
• Database of Abstracts of Reviews of Effects (DARE) to
October 2018;
• Health Technology Assessment database to October 2018;
• Web of Science to October 2018.
Searching other resources
We also searched for unpublished material on Scopus (
www.scopus.com). We checked the reference lists of all the studies
identified by the above methods and contacted other authors and
trialists in the field.
Data collection and analysis
Selection of studies
Two review authors (PD, RB) independently assessed the abstract
(if available) of each reference identified by the search against
the inclusion criteria. We resolved any disagreements that arose
through discussion and consensus with a third author (MC). For
the update review, we screened the search results using Covidence
2014. We retrieved those references that potentially met the in-
clusion criteria (based on their abstract or title) in full for further
independent assessment.
Data extraction and management
We extracted the following data from each included study.
• Study design
• Study population
• Reference standard and performance of the reference
standard
• Performance of the index test
• Technical details of the PCR methods used, including
genetic target of PCR and nucleotide probe sequence, and any
PCR testing methods; we classified the diagnostic modalities
using PCR assays according to the sampling methods and how
these relate to the definition of a positive result, namely either
positive PCR in at least two consecutive blood samples drawn
from the same patient, or a single sample yielding a PCR positive
result. When we compared PCR-based tests to GM, we assessed
whether authors explicitly mention the exclusion of the GM
ELISA test from the reference test definition (EORTC/MSG
criteria). In this case, we performed a direct comparison of the
index test and the comparator evaluated in the same study
population towards the reference standard.
• QUADAS-2 items
• Data for two-by-two table (false-positive, true-positive,
false-negative and true-negative results of the diagnostic tests
under investigation and reference standard).
Pairs of authors extracted the data; they resolved disagreements by
discussion.
Assessment of methodological quality
Assessment of the quality of diagnostic accuracy studies, as recom-
mended in STARD (Standards for Reporting of Diagnostic Accu-
racy), is of absolute relevance in systematic reviews (Bossuyt 2003;
Reitsma 2009;Whiting 2004). For this purpose, we used theQual-
ity Assessment tool for Diagnostic Accuracy Studies (QUADAS-
2) tool , the current version of QUADAS that has been adopted
for use by Cochrane and is recommended for use in all Cochrane
diagnostic test accuracy reviews to evaluate the risk of bias and ap-
plicability of primary diagnostic accuracy studies. Pairs of authors
independently assessed the methodological quality of the studies
included, and disagreements were resolved by consensus with all
of the authors.
QUADAS-2 consists of the following four key domains.
• Patient selection
• Index test
• Reference standard
• Flow and timing
Each is assessed in terms of risk of bias and the first three in
terms of concerns regarding applicability. Signalling questions are
included to assist in judgements about risk of bias. Risk of bias is
judged as ’low’, ’high’, or ’unclear’. If all signalling questions for
a domain are answered ’yes’ then risk of bias can be judged ’low’.
If any signalling question is answered ’no’ this flags the potential
for bias. The ’unclear’ category is used only when insufficient data
are reported to permit a judgment.
Tabular and graphical displays are used to summarise QUADAS-2
assessments. We did not calculate a summary score estimating the
overall quality of an article, since their interpretation is problematic
and potentially misleading (Whiting 2005).
The items of the QUADAS-2 tool and their interpretation are
reported in appendix (Appendix 2).
Statistical analysis and data synthesis
The values of sensitivity and specificity are automatically com-
puted in Review Manager 2014. We obtained summary positive
8Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(LR+) and negative (LR−) likelihood ratios from the bivariate
analysis (see below). We evaluated different interpretive criteria
for a PCR-positive result in the two-by-two table, namely a sin-
gle positive PCR result and two positive PCR results. We have
presented individual study results graphically by plotting the es-
timates of sensitivity and specificity (and their 95% confidence
intervals (CIs)) in both forest plots and receiver operating charac-
teristics (ROC) space.
We assessed the operating point sensitivity and specificity of the
diagnostic test under scrutiny by a bivariate random-effects ap-
proach (Reitsma 2005). The original method was modified by
using a random-effects bivariate logistic model (Chu 2006). The
same procedure permits generation of a hierarchical summary re-
ceiver operating characteristic (HSROC) model (Rutter 2001).
The bivariate approach examines the influence of covariates on
sensitivity and specificity (or both), whilst the HSROC model is
focused on threshold and accuracy (Guo 2015; Harbord 2007). In
most conditions bivariate andHSROC are equivalent, particularly
in the absence of covariates. When there is a considerable degree of
between-study heterogeneity, as is common in meta-analysis of di-
agnostic accuracy studies, a prediction region may be preferable to
a confidence region(Harbord 2007); this is assured by the bivariate
approach. The results of the bivariate model can be used to cal-
culate likelihood ratios. To calculate (negative) predictive values,
an estimate of prevalence in addition to values of sensitivity and
specificity is required. One can then apply a Bayesian approach
to obtain predictive values from these three parameters. We per-
formed bivariate analysis using STATA 11 software. We compared
the diagnostic measures of diagnostic accuracy and related 95%
CIs by adding binary covariates to the bivariate model.
Investigations of heterogeneity
We assessed heterogeneity by visual inspection of forest plots of
sensitivity and specificity, and through visual examination of ROC
plot of the raw data. We further investigated heterogeneity by ex-
ploring the effects of several study-level covariates. For this, we per-
formed a multilevel mixed-effects logistic model using the proba-
bility of test positivity as a dependent variable; the group variable
was the study, and the disease status was the first explanatory vari-
able. This basic model admitted in turn several additional covari-
ates. When available, we examined the following covariates.
• Distinctive groups of patients
• Study size (< or ≥ 100 patients)
• Children versus adults
• Use of antifungal prophylaxis active against Aspergillus
species
• Variation in PCR techniques (RT-PCR versus other PCR
methods)
We included the interaction between the disease status and the
additional covariate into the model as well.
We have analysed the potential influence of risk of bias (e.g. blind-
ing of the index test, blinding of the reference test) by sensitivity
analysis.
R E S U L T S
Results of the search
Of the 2474 references identified, we selected 215 potentially rel-
evant citations (Figure 1). After screening titles and abstracts, we
selected 91 articles for full-text review. Of these, we excluded 62
studies for various reasons (Characteristics of excluded studies):
patients were selected retrospectively in 11 studies; 20 studies did
not provide sensitivity and/or specificity data for two-by-two ta-
bles; 13 were case-control studies; four studies included BAL only
or tissue PCR; 3 studies included a subset of previous trials; the in-
dex test was inappropriate in 6 studies and the reference standard
was inappropriate in 7 studies; 2 studies were in Chinese; 3 studies
were duplicates of previously published papers; and, finally, 2 for
other reasons. Therefore, 29 studies published between 2000 and
2018met the inclusion criteria andwere included in themeta-anal-
ysis (Aslan 2015; Badiee 2010; Badiee 2017; Barnes 2009; Barnes
2013; Bellanger 2015; Boch 2016; Boluk 2016; Cuenca-Estrella
2009; da Silva 2010; El Mahallawy 2006; Ferns 2002; Florent
2006;Halliday2006;Hebart 2000a;Hummel 2009; Imbert 2016;
Landlinger 2010; Loeffler 2017; Pini 2015; Ramírez 2009; Rogers
2013; Schwarzinger 2013; Springer 2011; Springer 2016; Suarez
2008; Sugawara 2013; von Lilienfeld-Toal 2009; White 2006).
Three studies reported the diagnostic performance of PCR per-
formed with different methodologies (Aslan 2015; Rogers 2013;
Suarez 2008), and one in a different patient setting (Rogers 2013).
Therefore data were analysed from 34 data sets.
9Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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The main characteristics of the studies are summarized in the
Characteristics of included studies tables. More than 28,000 clin-
ical blood specimens from 4718 patients at risk of IA were in-
cluded.Most had received chemotherapy for a haematological ma-
lignancy or had been given a hematopoietic stem cell transplant
(HSCT). The PCR techniques used are summarized in Table 2.
Twenty-eight of the selected studies (corresponding to 33 data
sets) reported the results of a single PCR result, and nine studies
(13 data sets) reported using two PCR results. In three studies it
was possible to extract the two-by-two data in subsets of patients
receiving or not receiving anti-mould prophylaxis (Imbert 2016;
Rogers 2013; Springer 2016). Sixteen of the studies included in the
analysis also reported results of GM assay (Barnes 2009; Bellanger
2015; Cuenca-Estrella 2009; da Silva 2010; El Mahallawy 2006;
Ferns 2002; Florent 2006; Hummel 2009; Imbert 2016; Loeffler
2017; Rogers 2013; Schwarzinger 2013; Springer 2011; Springer
2016; Suarez 2008; Sugawara 2013). The study by Rogers 2013
presented two cohorts of patients (one from the University Clinic
of Wurzburg, and one from Saint James’s Hospital, Dublin) ac-
cording to the PCR test used: Internal Transcribed Spacer (ITS)
qPCR and the 28S nested PCR; the study by Suarez 2008 pre-
sented data according to the protocols for serum processing (large
and small volume); and the study by Aslan 2015 according to two
PCR tests used (in-house and commercially available test).
Methodological quality of included studies
We summarize the quality of studies as assessed by the QUADAS-
2 tool in tables and graphs. Figure 2 shows the overall risk of bias
and applicability concerns for the 29 selected studies. Figure 3
presents the quality assessment results for the individual studies.
For all QUADAS-2 domains, most studies were at low risk of bias
and low concern regarding applicability. In the patient selection
domain, all the studies enrolled a homogenous and representative
population of patients at risk of IA; 75% of studies were at low
risk of bias because they enrolled participants consecutively and
avoided inappropriate exclusions. We graded six studies as being
at unclear risk of bias because the manner of patient selection was
not stated; and we graded one study at high risk of bias because it
included retrospectively a heterogeneous population with various
underlying diseases, mostly haematologic and neutropenic, but
also patients with a non-invasive form of aspergillosis.
Figure 2. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies
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Figure 3. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study
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In the index test domain, we considered 50% of studies to be at
low risk of bias and 70% of studies to be at low concern regarding
applicability. We judged the remaining studies to be at unclear
risk of bias because it was unclear if the index test was performed
knowing the results of the reference standard. In the reference
standard domain, we judged around 70% of studies to be at low
risk of bias because it was stated that the reference standard results
were interpreted without knowledge of the results of the index test,
while in the remaining studies it was not specified. Applicability
was of low concern for almost all studies in the reference standard
domain. In the flow and timing domain, we judged 70% of studies
to be at low risk of bias because all patients were accounted for
in the analysis, the appropriate reference standard was used, and
information about uninterpretable results was provided. We had
nearly complete information for all studies.
Findings
Results of the meta-analysis
Based on 29 included studies, the median number of patients per
study was 99 (range 17 to 549), and themean prevalence of proven
or probable IA was 16.3% (median 11.1, range 2.5% to 57.1%).
The sensitivity and specificity of PCR for the diagnosis of IA var-
ied according to the interpretative criteria used to define a test as
positive. For PCR assays, we evaluated the requirement for either
one or two consecutive samples to be positive for diagnostic accu-
racy.With the one positive requirement, the sensitivity reported in
the studies ranged from 22% to 100%, and specificity from 2% to
100%.With the two positive requirements the sensitivity reported
in the included studies ranged from 0% to 92%, and specificity
from 75% to 100%. The summary estimates of sensitivity and
specificity were 79.2% (95% CI 71.0% to 85.5%) and 79.6%
(95%CI 69.9% to 86.6%) for a single positive result requirement,
and59.6%(95%CI40.7% to 76.0%) and95.1%(95%CI87.0%
to 98.2%) for two positive results requirement. LR+/LR− were
3.8 (95% CI 2.6 to 5.7)/0.26 (95% CI 0.18 to 0.36) for a single
positive result, and 12.2 (95% CI 4.2 to 35.3)/0.42 (95% CI 0.26
to 0.67) for two positive results. When used in isolation, a single
PCR positive test as diagnostic criterion for IA in a population
of 100 people with a disease prevalence of 16.3% (overall mean
prevalence), three people who have IAwould bemissed (sensitivity
79.2%, 20.8% false negatives), and 17 people would be unnec-
essarily treated or referred for further tests (specificity of 79.6%,
21.4% false positive). If we use the ’two positive tests’ requirement
in a population with the same disease prevalence, it would mean
that nine IA people would be missed (sensitivity 59.6%, 40.4%
false negatives) and four people would be unnecessarily treated or
referred for further tests (specificity of 95.1%, 4.9% false positive).
Heterogeneity
The appearance of the forest plots for PCR show a wide range
of diagnostic indices at study level; this was more apparent for
specificity using the ’single positive’ requirement, and for sensi-
tivity using the ’two positive’ requirement. (Figure 4; Figure 5).
Visual inspection of the prediction ellipses in the bivariate analysis
show a large area occupying most of the full probabilistic space;
the degree of eccentricity was more pronounced in the specificity
direction for a ’single positive’ requirement, and in the sensitivity
direction for ’two positives’ requirement (Figure 6; Figure 7).
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Figure 4. Forest plot of PCR: one (single) positive requirement.
Figure 5. Forest plot of PCR: two positive requirement.
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Figure 6. Summary ROC Plot. Bivariate analysis of the sensitivity and specificity of the PCR as a diagnostic
tool for Aspergillus invasive infection. One single positive PCR result is required to define the test as positive
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Figure 7. Summary ROC Plot. Bivariate analysis of the sensitivity and specificity of the PCR as a diagnostic
tool for Aspergillus invasive infection. Two or more consecutive positive PCR result are required to define the
test as positive.
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We investigate heterogeneity by subgroups analyses.
Bivariate analysis
Graphs (ellipses) of bivariate models for the two different criteria
for PCRpositivity are shown inFigure 6 andFigure 7.We excluded
unpaired studies for the evaluation of the differential effect of the
single positive/two positive criterion. We reduced the number of
studies included in the paired analysis to eight, corresponding to
12 comparisons of PCR test (each paired for ’single positive’ and
’two positive’ criteria; Badiee 2010; Barnes 2013; Cuenca-Estrella
2009; Florent 2006; Halliday 2006; Rogers 2013; Springer 2011;
Suarez 2008). When sensitivity and specificity data from the bi-
variate model were compared, changing the ’positive results’ re-
quirement from one to two increased specificity significantly from
79.5% to 95.1% ( P value < 0.0001). By contrast, the sensitivity
decreased significantly from 79.2% to 59.6% (P value < 0.0001).
The joint effect on sensitivity and specificity was also significant
(P value < 0.0001) (Table 3).
Subgroups analysis and bivariate analysis with covariates
We carried out a subgroup analysis of adult and paediatric studies
(Boch 2016; El Mahallawy 2006; Halliday 2006; Hummel 2009;
Landlinger 2010). The diagnostic yield did not differ significantly
between adult and paediatric studies. However, the limited num-
ber of paediatric studies does not allow a firm conclusion to be
drawn regarding the diagnostic performance of PCR in paedi-
atric patients. We also performed a subgroup analysis according to
study size. Studies were defined as small size (15 studies) or large
size (14 studies) according to the number of enrolled people (< or
≥ 100). Likewise study size did not have a significant impact on
performance of PCR test.
We also performed a subgroup analysis of studies endorsing 2002
EORTC criteria (10 studies: El Mahallawy 2006; Ferns 2002;
Florent 2006; Halliday 2006; Hebart 2000a; Hummel 2009;
Ramírez 2009; Suarez 2008; von Lilienfeld-Toal 2009; White
2006) or 2008 criteria (seven studies: Badiee 2010; Barnes 2009;
Cuenca-Estrella 2009; da Silva 2010; Rogers 2013; Springer 2011;
Sugawara 2013), using the bivariate method and considering the
results of PCR test with the ’single positive’ criterion. One study
stated the use of EORTC criteria but did not mention which crite-
ria were employed (Landlinger 2010). Lower sensitivity and speci-
ficity values were found for studies using 2008 criteria compared
to those using 2002 criteria (73.1% (95% CI 63.2 to 81.1) and
73.3% (95% CI 60.9 to 82.9) versus 78.7% (95% CI 70.6 to
85.1) and 82.2% (95% CI 65.5 to 91.8), respectively), but these
differences were not statistically significant and probably driven
by the low estimates of diagnostic accuracy found in some of the
2008 studies (Rogers 2013; Springer 2011) (Table 3).
Twelve studies used anti-mould prophylaxis (itraconazole,
voriconazole, amphotericins or caspofungin) in the entire pop-
ulation or in a subset of patients under investigation ( Barnes
2009; Barnes 2013; Cuenca-Estrella 2009; Ferns 2002; Florent
2006; Hummel 2009; Imbert 2016; Loeffler 2017; Rogers 2013;
Springer 2016; Sugawara 2013; White 2006) ; ). Thirteen stud-
ies did not use antimould prophylaxis at all (Badiee 2010;Badiee
2017; Boch 2016; Boluk 2016; da Silva 2010; ElMahallawy 2006;
Halliday 2006 Hebart 2000a; Landlinger 2010; Rogers 2013;
Schwarzinger 2013; von Lilienfeld-Toal 2009); or only in a subset
of patients (Imbert 2016; Springer 2016). Fluconazole was used as
prophylaxis in four studies (Badiee 2010; Halliday 2006; Hebart
2000a; Springer 2011). When examining data under the criterion
’single positive’, the anti-mould prophylaxis produced a significant
reduction of specificity (from 0.79 (95% CI 0.67 to 0.87) to 0.64
(95% CI 0.56 to 0.72), coupled with no significant increase of
sensitivity (from 0.75 (95% CI 0.64 to 0.84) to 0.82 (95% CI
0.75 to 0.87) (Data table 4).
The PCR methods varied notably. Some studies were based on
gel electrophoretic visualization after proper staining of the ampli-
cons, whereas others were based on automated procedures, such as
real-time PCR, with substantial differences regarding the thresh-
old of detection. We relied on the reported qualitative (positive/
negative) test results only, and did not take the possible cut-point/
threshold variation across studies into consideration. Compari-
son of the three studies - Aslan 2015, Boluk 2016 and Pini 2015
- analyzed in this review that used kit-based assays to 15 stud-
ies (Badiee 2010; Badiee 2017; Bellanger 2015; Cuenca-Estrella
2009; Imbert 2016; Landlinger 2010; Loeffler 2017; Ramírez
2009; Rogers 2013; Schwarzinger 2013; Springer 2011; Springer
2016; Suarez 2008; von Lilienfeld-Toal 2009) that used in-house
qPCR assays (excluding end-point or nested PCR) did not reveal
any statistically significant differences between kit and in-house
assays. There was a trend for greater sensitivity and specificity for
the in-house assays compared to commercially available kits (0.74
vs 0.65; 0.84 vs 0.76, respectively), although these differences did
not reach statistical significance.Whole blood PCR test had higher
sensitivity and lower specificity compared to serum PCR test, but
these differences were not statistically significant (Table 3).
Quality items that did have an effect on sensitivity or specificity
were blinding of the index test (4%decrease in sensitivity and 17%
decrease in specificity) and blinding of the reference standard (5%
decrease in sensitivity and 14% decrease in specificity). In other
words, failure of blinding produced a spurious increase in overall
accuracy.
Predictive values
Positive and negative predictive value (PPV andNPV, respectively)
of Aspergillus PCR detection are shown in Figure 8 (Figure 8).
The predictive values were calculated by applying the Bayes rule.
The use of the two positive criteria produces a significant increase
in the PPVs, and only a slight decrease of NPVs. With a mean
prevalence of invasive aspergillosis of 16%, the PPV is 42.8% with
a ’single positive test’ criterion, and 70.3% with ’two positive tests’
criterion; forNPV these figures are 95.1%and92.4%, respectively.
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Figure 8. Predictive values. Positive and negative predictive value (PPV and NPV, respectively) of the
Aspergillus PCR detection test (y-axis) as a function of the prevalence of the disease, invasive aspergillosis (x-
axis). The curves are related to the diagnostic criterion (a single positive result or two consecutive positive
PCR results). The PVs were calculated by applying the Bayes rule. The mean prevalence of invasive
aspergillosis (16.3%) is indicated by the vertical dashed line. It corresponds to PPV1 = 42%, NPV1 = 95%, PPV2
= 70%, NPV2 = 92%.
Comparison between PCR techniques and GM assay
Sixteen studies also evaluated GM assay (Barnes 2009; Bellanger
2015; Cuenca-Estrella 2009; da Silva 2010; El Mahallawy 2006;
Ferns 2002; Florent 2006; Hummel 2009; Imbert 2016; Loeffler
2017; Rogers 2013; Schwarzinger 2013; Springer 2011; Springer
2016; Suarez 2008; Sugawara 2013), but in all studies but one
GM was part of the reference standard (Suarez 2008). Thus to
avoid incorporation bias, we did not compare data of GM assay
to PCR, and did not include them in the current review.
In the study by Suarez 2008, sensitivity and specificity were 100%
and96.7% for qPCRusing large sample volume (LSV), and88.2%
and 95.8% for GM. Thus the overall performance of qPCR using
LSV was consistently higher than that of GM.
D I S C U S S I O N
Summary of main results
We included 29 primary studies, corresponding to 34 data sets, in
the meta-analyses: 18 RCTs were included in the original review,
and we identified 11 additional trials for this update. The mean
prevalence of IA (proven or probable) in the included studies was
16.3%. The majority of patients had received chemotherapy for
a haematological malignancy or had been given a hematopoietic
stem cell transplant (HSCT). Several PCR techniques were used
among the included studies. The sensitivity and specificity of PCR
for the diagnosis of IA varied according to the interpretative cri-
teria used to define a test as positive. For PCR assays, we eval-
uated for diagnostic accuracy the requirement for either one or
two consecutive samples to be positive. The summary estimate of
sensitivity and specificity were 79.2% (95% CI 71.0% to 85.5%)
and 79.6% (69.9% to 86.6%) for a single positive test result, and
59.6% (40.7% to 76.0%) and 95.1% (87.0% to 98.2%) for two
positive test results. The findings indicate that PCR shows mod-
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erate diagnostic accuracy when used as a screening test for inva-
sive aspergillosis in high-risk patient groups. We found several co-
variates (in particular, the adoption of antifungal prophylaxis and
blinding to the reference test or index test) to substantially affect
the measures of diagnostic accuracy under evaluation, particularly
sensitivity and specificity. The uneven distribution of these covari-
ates may explain, at least partly, the large heterogeneity found in
this analysis. The subgroup analyses suggest that antifungal pro-
phylaxis might impair performance and these conclusions may not
be applicable to patients on concurrent antifungal therapy.
Strengths and weaknesses of the review
The findings of this review are based on comprehensive search-
ing, strict inclusion criteria, and standardized data extraction. The
strength of our review is that it enables an assessment of the diag-
nostic accuracy of PCR for detection of IA in a homogenous pop-
ulation of patients at risk of IA. We used the strict inclusion crite-
ria (cohort of consecutive patients, including neutropenic cancer
patients and hematopoietic stem cell or solid organ transplant re-
cipients) to cover the spectrum of diseases likely to be encountered
in the current or future use of this diagnostic test.
We only included studies that used the EORTC/MSG criteria or
a similar reference standard. Differences in the reference standard
may have contributed to differences we found in the distribution
of patients with probable, possible and no invasive aspergillosis,
but not ’proven disease’ as this relies on demonstration of the
fungus in tissue. For instance, the clinical features in the revised
definitions are based solely on radiological evidence of IA whereas
the original 2002 definitions also included minor signs such as
fever and cough as evidence of disease. Consequently, employing
the revised definitions to cases classified as possible IA by the 2002
definitions would only be retained as such if there was radiological
evidence. Applying the 2008definitionswould have a similar effect
on probable IA for the same reasons.
Anti-mould prophylaxis reduces the proportion of proven/prob-
able cases of IA (according to EORTC/MSG criteria) which is
associated with a lower specificity of the Aspergillus PCR testing of
blood. It is likely that PCR can detect infection before overt disease
is radiologically detectable. Consequently, people with positive re-
sults who did not meet the criteria for proven or probable disease
could have had early infection that resolved either with empirical
or pre-emptive antifungal treatment or as a result of resolution of
the underlying immunosuppression.
The antifungal administration could mask a proportion of in-
vasive infections, thus lowering the diagnostic recognition of a
proportion of them. A raw calculation indicates a prevalence of
17.4% without prophylaxis, 10.4% with prophylaxis. Meanwhile,
the PCR could maintain its ability to detect the Aspergillus DNA
in the blood of the patients. Alternatively, the prophylaxis could
maintain the fungal growth in a pre-invasive stage, though not
impeding the shedding of genomic material into the circulation,
possibly enhancing its release through damage to the fungal cell
wall or membrane.
The lack of direct comparisons with other biomarkers including
GM and beta-D-glucan could be a further shortcoming. Looking
at our findings and at those of other reviews, the performance of
the PCR test is comparable to that reported for GM and supe-
rior to beta-D-glucan. It is likely that combinations of different
biomarkers will provide the optimal diagnostic performance. Also
it was difficult to distinguish between using PCR for screening
purposes and for confirming the diagnosis as these are associated
with low and high a priori likelihood respectively. Furthermore,
screening requires testing at regular intervals during the period of
risk (typically every 3 to 4 days) whereas tests for confirming the
diagnosis of IFD will only be done once.
The molecular basis for azole resistance has been described, and
the ability to detect Aspergillus DNA also raises the possibility of
rapid detection of antifungal resistance using the same specimen.
This could optimise patient management further and should be
explored in future studies.
Applicability of findings to the review question
Wenoted thatmost studies performed PCR in high-level reference
laboratories, but it is not clear whether intermediate/peripheral
laboratories might be settings that match the review question. An
important step towards the standardisation andwidespread uptake
of PCR-based diagnosis for aspergillosis will be the adoption of
effective kit-based assays. Much has been done by the EAPCRI to
establish a standard for PCR that should help laboratories offer-
ing the test ( www.eapcri.eu). However incorporating PCR into
routine practice also requires an explicit protocol indicating who
should be tested, when and how frequently, as well as what action
should be taken in the event of a given result (Barnes 2018).More-
over the process needs to be completed within a frame so that the
results can be used to best advantage by the clinician. This requires
an explicit care plan or pathway, a multidisciplinary approach and
a clear understanding between the clinic and laboratory to ensure
a smooth turnaround.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The findings indicate that PCR screening tests show moderately
good diagnostic accuracy when used as screening tests for IA in
high-risk patient groups. For a screening strategy, however, with
the low prevalence of IA in the observed population and a low pre-
test probability of disease, the moderate sensitivity of the PCR is
sufficient to ensure a good negative predictive value, such that dis-
ease can be confidently excluded and the need for empiric therapy
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avoided. As such, screening strategies could replace empirical anti-
fungal therapy in selected high-risk patients. Consecutive positive
test results show excellent specificity in the diagnosis of IA and
could be used to trigger radiological and other investigations or for
pre-emptive therapy in the absence of specific radiological signs
when the clinical suspicion of infection is high. The subgroup
analyses suggest that antifungal prophylaxis could impair perfor-
mance and these conclusions may not be applicable to people on
concurrent antifungal therapy. With the observed prevalence of
disease (16.3%), repetition of the PCR test increase considerably
the positive predictive values, with a modest decline of the nega-
tive predictive values. Therefore we recommend the repetition of
the PCR assay in order to increase the diagnostic accuracy.
Implications for research
It is clear that PCR holds a lot of promise as a useful test for detect-
ing Aspergillus infection although the diagnostic accuracy might
be improved further by combining the test with other biomarkers
such as GM, and this should be explored in future studies. Fur-
ther validation is also needed to determine whether using PCR
for screening high-risk patients, not on anti-mould prophylaxis,
could become the standard of care. Future studies that validate
PCR for aspergillosis clearly need to distinguish between use of
the test to screen for the presence or absence of IA in high-risk
patients if there are no signs of illness, and its use to confirm or
exclude the disease when it becomes manifest. IA can be ruled out
during the risk period for as long as any single PCR test is negative
and there are no clinical signs of disease. Conversely when preva-
lence of aspergillosis is around 10%, two or more PCR positive
results can be used for mycological confirmation to allow a case of
possible IA to be upgraded to probable.
The tests need to be incorporated into patient care pathways that
compare prophylactic, empirical, pre-emptive and targeted anti-
fungal drug use looking at impacts on patient management.
It was not possible to investigate the diagnostic utility of combina-
tions of biomarkers (e.g. PCR and GM) because the GM is incor-
porated into the EORTC/MSG definitions and would introduce
incorporation bias. Hence, cases would have to be classified by
omitting GM. Further studies are needed to assess clinical utility
and cost effectiveness.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aslan 2015
Study characteristics
Patient sampling Neutropenic patients at risk of IA were prospectively included in the trial between January 2011
and January 2012
Patient characteristics and set-
ting
161 febrile neutropenic episodes of 99 patients. Haematology and SCT patients with fever. Uni-
versity Hospital in Turkey
Index tests 2 PCR tests were used: an In-house real-time PCR and a commercially available test (MAP-My-
conostica Ltd, Manchester, UK). GM also performed
Target condition and reference
standard(s)
Patients were evaluated for IA; cases of IA were defined according to the EORTC/MSG revised
criteria (incorrectly used)
Flow and timing January 2011 to January 2012
Comparative
Notes A control group of patients not at risk of IAwas also included, but it was possible to extract sensitivity
and specificity data just from the relevant clinical population
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Aslan 2015 (Continued)
If a threshold was used, was it
pre-specified?
No
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Badiee 2010
Study characteristics
Patient sampling Prospective study, samples collected September 2004 to June 2006. Patients with haematological
malignancies (who had received chemotherapy)
Patient characteristics and set-
ting
Sample size: 194
Males/females: 133/61
Mean age: 33.7 years (range 14 to 80)
Presentation: patients with haematological malignancies and solid organ transplantation at risk for
IFD
Setting: Nemazi Hospital, Shiraz, Iran
Index tests DNA extracted through lysis of blood and fungal cells (Van Burik 1998) followed by purification
using the QIAamp DNA Mini Kit. Standard PCR was used as well as PCR-ELISA. . Presence or
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Badiee 2010 (Continued)
absence of bands indicated a positive result; positive results were retested with species-specific probes
Target condition and reference
standard(s)
Patients were evaluated for IA; patient samples (urine, cerebrospinal fluid, pleural and abdominal
tap, BAL and sputum) were examined for signs of infection. Cases of IA were defined according to
the EORTC/MSG 2002 criteria
Flow and timing Samples were collected from 209 patients between September 2004 and June 2006; 985 samples
collected from 194 patients were analysed. Blood samples (EDTA) were collected once per week
and frozen prior to analysis. Patients were excluded if they did not attend follow-up for more than
2 weeks. No indication that patients with possible IA were excluded from 2 × 2 analysis
Comparative
Notes This study describes the performance of standard PCR and PCR-ELISA
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Badiee 2010 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
No
Unclear
Badiee 2017
Study characteristics
Patient sampling Consecutive patients
Patient characteristics and set-
ting
86 haematologic paediatric patients. Shiraz University of Medical Science, Iran
Index tests real time PCR for candidiasis and aspergillosis
Target condition and reference
standard(s)
IFI; EORTC/MSG revised criteria
Flow and timing from January 2014 to February 2015
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Badiee 2017 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Barnes 2009
Study characteristics
Patient sampling Prospective study between October 2005 and March 2006; at risk febrile patients or SCT patients
with graft-versus-host disease
were tested
Patient characteristics and set-
ting
Sample size: 125 patients
Males/females: 1.4/1
Mean age: 56.2 years (range 16 to 83)
Presentation: haematology patients at risk for IFD including SCT, acute myeloid leukemia
Setting: University Hospital of Wales
Index tests DNA extracted from 2ml blood, red cell lysis, white cell lysis, bead beating andMagna Pure (Roche)
DNA purification (White 2006). Nested PCR with second round on LightCycler (Roche) targeting
28S, 60 cycles all together. All positive samples were repeated
Target condition and reference
standard(s)
IFDwas the target condition for PCR assays; GMantigen testing was performed on patient samples,
EORTC/MSG 2008 criteria (including GM) were used to define cases of IFD
Flow and timing 1028 specimens collected from 125 patients over a 6-month period. 130 patients were screened but
125 were evaluable. No indication that patients were excluded from 2 × 2 analysis; this analysis was
performed for “single non-reproducible positive PCR”, “Single reproducible positive PCR” and
“multiple positive PCR” results
Comparative
Notes Report examines diagnostic-driven care pathway, limited empirical treatment. Data provided for
interpretation of single and reproducible results. Very relevant to this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
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Barnes 2009 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Low
Barnes 2013
Study characteristics
Patient sampling Prospective, consecutive
Patient characteristics and set-
ting
Sample size: 612 patients, excluded 27 children, 36 due to sample size (> 2) males/females: ? Mean
age: ?
Presentation: febrile or history of fungal infection orSCT with GVHD
Setting: hospital in Cardiff
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Barnes 2013 (Continued)
Index tests Aspergillus PCR (Barnes 2009; Lewis 2006)
Target condition and reference
standard(s)
Invasive aspergillosis. EORTC/MSG criteria
Flow and timing Between Oct 2005 and June 2009 all adult patients entered into the pathway were audited. Fungal
diagnostic test (antigen and PCR) were performed twice weekly in SCT patients and during fever
in other patients
Comparative
Notes comparison of single vs double PCR positives; EORTC classification with/without GM/serum.
Patients received itraconazole prophylaxis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Barnes 2013 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
Unclear
Unclear
Bellanger 2015
Study characteristics
Patient sampling consecutive sample of patients
Patient characteristics and set-
ting
Sample size: 185 patients
Males/females: not stated
Mean age: not stated
Presentation: inclusion based on risk factors for IA including prolonged neutropenia and aplasia.
Setting: haematology ICU, University Hospital Besancon, France
Index tests 18S and Mito
Target condition and reference
standard(s)
Invasive aspergillosis. 2008 EORTC/MSG criteria
Flow and timing Twice weekly serum samples
Comparative
Notes GM and beta-glucan also performed
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Bellanger 2015 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
Yes
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Bellanger 2015 (Continued)
Unclear
Boch 2016
Study characteristics
Patient sampling Prospective, consecutive patients
Patient characteristics and set-
ting
99 haematologic patients at risk of IA. Patients with CT signs suggestive of lung infiltrates under-
went BAL. University hospitals of Mannheim, Cologne, Essen, Wuerzburg, Regensburg, Erlangen,
Heidelberg, Prosper-Hospital Reckling-hausen and the General Hospital of Frankfurt/Oder
Index tests Diagnostic performance of a galactomannan (GM) enzyme immune assay (EIA), a 1,3-β-D-glucan
assay (BDG), an Aspergillus PCR, and a multifungal DNA-microarray (Chip) alone or in combi-
nation were calculated
Target condition and reference
standard(s)
Invasive aspergillosis. EORTC/MSG criteria
Flow and timing Patients were treated from 2012 to 2015
Comparative
Notes Calculation of diagnostic performance of GM and/or BDG was additionally carried out with the
exclusion of these test from defining probable IFD
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Unclear
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Boch 2016 (Continued)
dard?
If a threshold was used, was it
pre-specified?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Boluk 2016
Study characteristics
Patient sampling Prospective study with consecutive enrolment of patients, although not clearly stated
Patient characteristics and set-
ting
Sample size: 70 patients
Males/females: not stated
Mean age: not stated
Presentation: Inclusion based on risk factors for IA including neutropenia, recent use of immuno-
suppressive drugs including corticosteroids and persistent fever under broad spectrum antibiotic
therapy.
Setting: Hospital Haematology Clinic, Uludag University, Turkey
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Boluk 2016 (Continued)
Index tests They used a commercial PCR kit (Way2 Gene Fungi Kit() on a LightCycler 480 Probes Master. An
internal control was used for PCR
Target condition and reference
standard(s)
Invasive aspergillosis. Patients classified by the 2008 EORTC/MSG criteria
Flow and timing Twice weekly serum samples, stored and analysed retrospectively
Comparative
Notes There was no antifungal prophylaxis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Boluk 2016 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
Yes
Unclear
Cuenca-Estrella 2009
Study characteristics
Patient sampling Patients with febrile neutropenia considered at risk from IA were studied prospectively between
October 2004 and November 2005
Patient characteristics and set-
ting
Sample size: 83 patients
Males/females: 48/35
Mean age: 52 years
Presentation: patients with haematological malignancies and febrile neutropenia at risk for IA
Setting: Hospital Universitario 12 de Octubre in Madrid, Spain
Index tests DNA extraction: DNA was extracted from the samples using the QiampDNA Mini Kit (Qiagen,
Izasa, Madrid, Spain)
DNA detection: 2 µl of DNA from each sample were used for each RT-PCR, which contained a
final volume of 20 µl with 3 mM of Cl2Mg, 0.5 µM from each primer, and 0.4 µM of molecular
beacon probe. Preincubation was at 95 °C, followed by 45 denaturation cycles (15 s at 95 °C),
annealing (30 s at 56 °C), and extension (5 s at 72°C). Each experiment was run twice
Definition of positive assay: the results were considered positive when an exponential increase in
fluorescence was detected compared with that of the negative controls before cycle 40 of amplifica-
tion. The detection limit was 10 fg of DNA per µl of sample (cycle 42 of amplification)
Aspergillus-specific: analyses for at least 1, 2 or 3 positive PCR tests retesting. 2244 specimens tested
Target condition and reference
standard(s)
The definitions of proven, probable and possible IA were set according to the definitions of the
EORTC/MSG. HRCT and GM testing were also performed as a part of reference standard
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Cuenca-Estrella 2009 (Continued)
Flow and timing 4 weekly samples (2 blood and 2 serum) were taken during episodes of febrile neutropenia
Time interval sampling: 2004 to 05
Selection/exclusion for analysis: excluding patient 10, for whom the PCR result was negative, it was
possible to calculate the time gain in diagnosis for the PCR technique compared to that for HRCT
and GM for the other 11 patients with IA
Sampling/storage: years (range)
Analysis type: at least 2 consecutive positive PCR results missing/uninterpretable results: N
Comparative
Notes Prophylaxis: itraconazole; proven/probable/possible/no IA: 1/9/2; PCR effectiveness (replica/eluat
into PCR volume): 2 × 2 of 200 µl. The information collected on each patient, as well as the PCR
results, were entered in a database
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
No
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Cuenca-Estrella 2009 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
da Silva 2010
Study characteristics
Patient sampling From October 2000 to August 2003, 172 patients with haematologic malignancies and 27 patients
receiving high-dose chemotherapy in an autologous haematopoietic stem cell transplantation setting
were studied prospectively. All patients were screened by PCR twice a week since admitted in the
ward
Patient characteristics and set-
ting
Patients with haematological malignancies and febrile neutropenia at risk for IA
Median age 50 years
Male/female: 102/70
Setting: Hospital dos Capuchos, Lisbon, Portugal
Index tests Blood samples, BAL samples, fungal DNA extraction and PCR conditions were performed as
described in Van Burik 1998. The whole process of amplification was done using Taq polymerase
(Gibco BRL) and pan-fungal primers that bind to the conserved regions of the fungal 18S
rRNA gene sequence. Established PCR negative and positive controls were used in every assay. 1311
blood specimens tested
Target condition and reference
standard(s)
Fungal infections were classified according to EORTC/MSG revised consensus
Flow and timing Peripheral blood samples frompatients were screened twice weekly for bothmethods since admission
to the ward. If a positive value was obtained the patient would be screened every day for 3 consecutive
days in the first week and then twice weekly again
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da Silva 2010 (Continued)
Comparative
Notes The study also evaluated GM assay, but due to incorporation bias (GM is part of the reference
standard), these data were not included in the current review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
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da Silva 2010 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
El Mahallawy 2006
Study characteristics
Patient sampling Febrile, neutropenic paediatric cancer patients were prospectively sampled between April 2003 and
April 2004. Patients were included if they had antibiotic-resistant fever. Patients were given full
diagnostic work-ups for any signs of IFD
Patient characteristics and set-
ting
Sample size: 91 patients
Males/females: 37:25
Mean age: 8 (range 2 to 18)
Presentation: “at risk” for IA including febrile neutropenic cancer patients and fever not responding
to antibiotics
Setting: National Cancer Institute, Cairo University
Index tests Serum samples (unknown volume) were treated with Lyticase, then extracted using QIAamp DNA
Mini Kit (Qiagen), PCR amplified 420 bp products from 18S gene (universal fungal assay). Single
round conventional PCR with 30 cycles. Products detected on agarose gel
Target condition and reference
standard(s)
Target condition was IFD; CT scan, blood culture and Aspergillus antigen detection were used to
aid in defining cases of IFD according to the EORTC/MSG (2002) criteria
Flow and timing 91 patients tested, unknown sample numbers during 1 year period. All patients were included in
2 × 2 analysis to calculate sensitivity, etc
Comparative
Notes Pan-fungal conventional PCR used with low cycles, lack of specific IA information may be a problem
for inclusion
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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El Mahallawy 2006 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
Yes
Unclear
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Ferns 2002
Study characteristics
Patient sampling 94 blood samples from 17 patients at high risk of IA undergoing chemotherapy for acute leukaemia
(10) or undergoing allogenic BMT (7) on the haematology unit at the University College London
Hospital Trust were screened
Patient characteristics and set-
ting
Gender and age: not specified
Setting: University College London Hospital Trust
Index tests Aspergillus DNA, from whole blood samples, was amplified by nested PCR to detect a 135 bp
fragment in the mitochondrial region of Aspergillus fumigatus or Aspergillus flavus (121 bp)
Target condition and reference
standard(s)
IA in haematologic patients. The diagnosis of aspergillosis was classified into proven, probable or
possible on the basis of EORTC/MSG criteria
Flow and timing PCR results were retrospectively compared with clinical data and antifungal treatment
Comparative
Notes None of the 94 samples from the 17 patients were above the cut-off value when tested as serum in
the Platelia™ Aspergillus antigen ELISA
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
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Ferns 2002 (Continued)
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
Yes
Unclear
Florent 2006
Study characteristics
Patient sampling FromApril 2001 throughNovember 2002, all patients (> 15 years)with haematologicalmalignancies
who were routinely screened for GM detection were included in the study. Gender and age were
not specified. Setting was Hopital Saint-Louis and Hotel-Dieu, Paris
Patient characteristics and set-
ting
A total of 201 patients were enrolled in the study and had 256 consecutive episodes of neutropenia
(neutrophil count fewer than 500 cells/mL). During the high-risk periods for infection and until
absolute neutrophil counts increased to greater than 500 cells/mL, all patients were hospitalised in
protected facilities with high-efficiency particulate air filtration associated with laminar air flow for
patients undergoing allogeneic stem cell transplantation
Index tests DNA was extracted from both serum and fungal cultures by use of the QIAamp DNA Mini Kit
(Qiagen), in accordance with the manufacturer’s recommendations. 2 negative controls were used
in each DNA extraction experiment. The PCR-ELISA was performed using the serum sample that
was collected for GM detection, which was stored at −20 °C until processing. 1205 specimens
tested
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Florent 2006 (Continued)
Target condition and reference
standard(s)
The criteria proposed by the EORTC/MSG were used. To evaluate the performance of the GM
assay either alone or in combination with the PCR-ELISA, the results of the GM assay were not
included in the microbiological criteria for the diagnosis of probable IA
Flow and timing Single-positive results were defined as at least a single positive result, and consecutive positive results
were defined as at least 2 positive results obtained consecutively within 1 week. 34 patients did not
have consecutive serum samples that were collected within 1 week, and they were excluded from
the final analysis. Because of the uncertainty of the diagnosis in patients with possible IA, 3 separate
analyses were performed: the first included only proven and probable IA cases; the second included
proven and probable IA cases, and possible cases were considered to be proven IA cases; and the third
included proven and probable IA cases, and possible cases were not considered to be IA. Inhibitors
were detected in 18 serum samples, and these samples were excluded from the analysis
Comparative
Notes PCR-ELISA precocity in diagnosing IA was assessed in comparison with the timing of the clinical
suspicion of IA, the results of CT, and histological and microbiological criteria as defined by the
EORTC/MSG
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
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Florent 2006 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Unclear
Halliday 2006
Study characteristics
Patient sampling Prospective collection of samples from patients undergoing chemotherapy or HSCT who had de-
veloped febrile neutropenia between August 2002 and July 2003. Blood samples collected from
consecutive patients twice weekly; only patients from whom 3 samples were obtained per febrile
episode were analysed
Patient characteristics and set-
ting
Sample size: 65 patients
Males/females: 23:6
Mean age: 37 (range 16 to 62)
Presentation: episodes of febrile neutropenia in patients undergoing chemotherapy or HSCT
Setting: Westmead Hospital, NSW, Australia
Index tests Blood collected twice weekly; DNA extracted from 500 µl EDTA blood using the GenElute Mam-
malian Genomic DNA Kit (Sigma-Aldrich) with modified protocol that included RCLB, followed
by lyticase treatment; no bead beating. Conventional nested PCR no qPCR assay modified from
(Skladny 1999). Aspergillus specific targeting 18S. Sensitivity of 10 CFU/ml
Target condition and reference
standard(s)
Target condition was IA, classified according to the EORTC/MSG criteria (2002). IA defined at
the end of “at risk” episodes
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Halliday 2006 (Continued)
Flow and timing 998 blood samples from65 patients (29 adults and 36 children) were collected between August 2002
and July 2003. Separate 2 × 2 analyses were carried out to calculate sensitivity, etc, with possible
cases excluded, or with possible cases included as true negatives or true positives
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
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Halliday 2006 (Continued)
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Hebart 2000a
Study characteristics
Patient sampling Prospective sample collection from patients who had undergone allogenic SCT between 1996 and
1997. 5 ml EDTA was collected 2 to 4 times weekly from the time of admission until discharge or
death. Samples from multiple centres were analysed in Tübingen
Patient characteristics and set-
ting
Sample size: 84 patients
Males/females: not specified
Mean age: 35 years (range 17 to 57)
Presentation: patients had undergone allogeneic SCT
Setting: University Hospital Würzburg
Index tests DNA extracted from 5 ml blood as described by Einsele et al 1997 (JCM); PCR targeting 18S
with Aspergillus specific probe (Aspergillus fumigatus, flavus and versicolour) for slot blot testing (not
qPCR)
Target condition and reference
standard(s)
IA was the target condition; cases of proven IA were defined as recovery of Aspergillus from normally
sterile sites, positive culture or demonstration of hyphae from deep tissue biopsy and autopsy
specimens along with clinical symptoms. Probable IA was defined as the presence of clinical signs
and symptoms together with radiographic evidence compatible with IA and isolation of Aspergillus
from respiratory specimens.
Flow and timing 1193 samples from 84 patients collected twice weekly and processed twice weekly. 2 × 2 analysis to
calculate sensitivity, etc. Included all patients (possible was not defined). Parameters were calculated
for both early and late onset IA
Comparative
Notes This study utilises definitions of IA that are pre-EORTC/MSG. Generally seems a compatible study
Methodological quality
53Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hebart 2000a (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
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Hebart 2000a (Continued)
Were all patients included in the
analysis?
Yes
Low
Hummel 2009
Study characteristics
Patient sampling PCR results from all consecutive patients from 3 university children’s hospitals investigated between
November 2000 and January 2007 were evaluated in this study
Patient characteristics and set-
ting
Themajority of patients hadmalignant haematological diseases. Patients from 3 university children’s
hospitals
Index tests AspergillusDNAwas detected in clinical samples by an experimentally and clinically validated nested
PCR assay as described previously (Bucheidt 2001; Bucheidt 2004; Skladny 1999).
Target condition and reference
standard(s)
Invasive aspergillosis; EORTC/MSG criteria
Flow and timing between November 2000 and January 2007
Comparative
Notes Results of serological diagnostic techniques (GM assay, Platelia™ Aspergillus enzyme immunoassay;
Bio-Rad) and post-mortem histological examination were included for clinical classifications
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
55Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hummel 2009 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
No
If a threshold was used, was it
pre-specified?
Unclear
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Imbert 2016
Study characteristics
Patient sampling Retrospective single-centre analysis of all patients at risk of IA
Patient characteristics and set-
ting
Patients with various underlying diseases, mostly haematologic and neutropenic, but also patients
with non-invasive form of aspergillosis. Hôpital Pitié Salpêtrière, Paris
Index tests In-house A fumigatus real-time PCR
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Imbert 2016 (Continued)
Target condition and reference
standard(s)
Invasive aspergillosis and a subset of patients with non-invasive aspergillosis. EORTC/MSG criteria
Flow and timing GM and PCR performed in 970 patients, but clinical data available from 941 (5146 serum samples)
. Retrospective analysis of all patients at risk of IA from February 2012 and October 2014
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Imbert 2016 (Continued)
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Unclear
Landlinger 2010
Study characteristics
Patient sampling Clinical specimens from consecutive patients were prospectively collected
Patient characteristics and set-
ting
125 paediatric haemato-oncological patients undergoing intensive chemotherapy (65) or allogeneic
stem cell transplantation (60) were analysed during 150 episodes of febrile neutropenia
Index tests Pan-fungal RT-PCR
Target condition and reference
standard(s)
IA; EORTC/MSG criteria
Flow and timing Whenever possible, specimens were collected at first onset of fever, within 48 hours thereafter, and
at subsequent time points in the course of the febrile episode, upon availability
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Landlinger 2010 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Loeffler 2017
Study characteristics
Patient sampling Prospective biomarkers screening for IA in haematologic children (alloHSCT)
Patient characteristics and set-
ting
Haematologic children at risk of IA. University Children’s hospital , Wurzburg
Index tests PCR conducted according to the EAPCRI criteria. GM assay also performed
Target condition and reference
standard(s)
Invasive aspergillosis. EORTC/MSG criteria
Flow and timing Twice weekly systematic screening of high-risk children by GM and PCR. Patients screened from
2012 to 2015 were all selected for retrospective analysis
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard
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Loeffler 2017 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Pini 2015
Study characteristics
Patient sampling Prospective evaluation of patients at risk of IA. Of the 71 eligible patients, 64 were prospectively
enroled, while 7 were excluded for incomplete data collection
Patient characteristics and set-
ting
Haematologic and other patients at risk of IA (COPD, SOT, cancer receiving chemotherapy, cir-
rhosis)
Index tests Qualitative real-time PCR. GM also performed
Target condition and reference
standard(s)
Invasive aspergillosis. EORTC/MSG criteria for haematologic patients. For the other patients, the
criteria proposed by Meersseman 2004
Flow and timing From December 2011 to December 2013. 141 serum samples from 64 evaluable patients
Comparative
Notes
Methodological quality
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Pini 2015 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Pini 2015 (Continued)
Were all patients included in the
analysis?
No
Unclear
Ramírez 2009
Study characteristics
Patient sampling Prospective sampling of “at risk” patients for IFD between June 2004 and July 2006. Samples also
taken from patients for whom confirmation of IFD before, during and after treatment was required
Patient characteristics and set-
ting
Sample size: 127 patients
Males/females: 64/63
Mean age: 45 years (range 30 to 58)
Presentation: patients at risk for IA and those requiring confirmation of IFD
Setting: Hospital Universitario de Valme, Seville, Spain
Index tests DNA extracted from 5 ml blood (EDTA); used RCLB, glass bead disruption and QiaAmp DNA
Mini Kit. LightCycler assay as described by Loeffler 2000. 20 µl PCR included 10 µl templateDNA;
50 cycles; followed by melt-curve analysis. DNA extraction control included, no internal control
Target condition and reference
standard(s)
IA was the target condition; cases were defined according to the EORTC/MSG criteria (2002)
Flow and timing 948 clinical samples from 127 patients collected between June 2004 and July 2006. Samples pro-
cessed immediately or stored prior to processing. 2 × 2 analysis was not conducted. Study focused
on analytical sensitivity (60 fg Aspergillus DNA, or 5 to 20 conidia); 1% of the samples were PCR
positive
Comparative
Notes This study had 5 proven/probable cases, 17 possible
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Ramírez 2009 (Continued)
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Rogers 2013
Study characteristics
Patient sampling Consecutive patients at risk of IA. Age not specified
Patient characteristics and set-
ting
Patients undergoing remission-induction chemotherapy for acute leukaemia, lymphoma, or
myeloma, autologous or allogeneic bone marrow or stem cell transplant were eligible for inclusion.
Over the course of the study 146 patients were recruited from Trinity College Dublin & St. James’s
Hospital, Dublin, and 132 from the Department of Internal Medicine, University of Würzburg
Medical Centre, Würzburg, Germany
Index tests ITS qPCR assay targeting the ITS 1/5.8S ribosomal operon was performed as previously described
(Springer 2011)
Target condition and reference
standard(s)
The EORTC/MSG definitions were used for categorization of patients with IFD including IA
Flow and timing Patient blood samples were collected twice weekly; in UKW the EDTA blood samples were logged
and processed prospectively while, in SJH, they were frozen at 80 °C and processed in retrospective
batches. DNA extracts were stored at 20 °C until they were processed by the second PCR assay
Comparative
Notes GM was part of the EORTC/MSG criteria for IFD
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Rogers 2013 (Continued)
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Schwarzinger 2013
Study characteristics
Patient sampling Consecutive patients at risk of IA (185 patients with AML) with 2214 serum samples prospectively
included
Patient characteristics and set-
ting
Setting: the study was conducted in 13 French teaching hospitals
Index tests In-house R-T PCR not according to EAPCRI recommendations
Target condition and reference
standard(s)
IA was the target condition; cases were defined according to the EORTC/MSG criteria (2002)
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Schwarzinger 2013 (Continued)
Flow and timing GM and R-T PCR was taken twice-weekly. The entire set of samples comprised 2214 sera collected
from 185 patients
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
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Schwarzinger 2013 (Continued)
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Springer 2011
Study characteristics
Patient sampling Consecutive patients at high risk of IA. 536 specimens from 46 patients at high risk for invasive
fungal infection were collected
Patient characteristics and set-
ting
Patients at risk of IA after allogeneic SCT and patients receiving myeloablative chemotherapy with
an expected duration of neutropenia (leucocyte count of 1,000/L) of at least 10 days. 19 males
(mean age 51 years), 17 females (mean age 58 years)
Index tests Quantitative PCR and ITS semi quantitative RT-PCR assay
Target condition and reference
standard(s)
EORTC/MSG criteria
Flow and timing Between January and August 2009, blood samples from patients with a high risk of IFD, together
with clinical data, were collected
Comparative
Notes GM performed as a part of EORTC/MSG criteria for IA
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Springer 2011 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Springer 2016
Study characteristics
Patient sampling Prospective study with consecutive enrolment of patients.
Patient characteristics and set-
ting
Sample size: 213 patients with 2128 sera. Males/females: 132/81. Mean age: mean age for women:
53,5 years (range 22 to 80); men: 52,7 years (range 19 to 77). Presentation: in total 213 mostly HM
patients with 2128 sera were prospectively included during a 2-year period. Twice-weeekly serum
samples (GM and PCR) were taken from 203 Allogeneic HSCT patients and patients receiving
myelosuppressive chemotherapy for AML (n = 99) ALL (18) CLL (6),MDS (26) Lymphoma (21)
multiple myeloma (38) solid tumors (5). Setting: university hospitals in Germany and Austria
Index tests In-house R-T PCR according to EAPCRI recommendations
Target condition and reference
standard(s)
IA was the target condition; cases were defined according to the EORTC/MSG criteria (2002)
Flow and timing
Comparative
Notes GM and R-T PCR was taken twice-weekly. The entire set of samples comprised 2259 sera collected
from235 patients. 12 patients with fewer samples than 3, and samples showing any failure/inhibition
of the internal controle or the entire PCR reaction (n=56) were excluded
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Springer 2016 (Continued)
If a threshold was used, was it
pre-specified?
Unclear
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Suarez 2008
Study characteristics
Patient sampling All adult patients receiving allogeneic or autologous haematopoietic SCT, or intensive (induction,
consolidation, or salvage) chemotherapy for haematological malignancies were included in the study
Patient characteristics and set-
ting
124 patients (138 treatment episodes) at risk of IA in the adult Haematology and Bone Mar-
row Transplant Unit at Necker-Enfants Malades hospital, a tertiary-care university hospital (Paris,
France)
Index tests RT-PCR on 1342 specimens
Target condition and reference
standard(s)
EORTC/MSG-documented IA. The diagnosis of IA (proven, probable, or possible) was defined for
a given patient as the day on which the first clinical, radiological and/or microbiological EORTC/
MSG criteria, other than a GM-positive result, appeared
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Suarez 2008 (Continued)
Flow and timing This study was conducted prospectively from February 2006 toMarch 2007. The dates of diagnosis
and the dates on which the first positive test results for Aspergillus fumigatus DNA and GM were
recorded.
Comparative
Notes For GM, incorporation bias avoided
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
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Suarez 2008 (Continued)
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Sugawara 2013
Study characteristics
Patient sampling Prospective analysis of consecutive blood samples from patients at risk for IFD
Patient characteristics and set-
ting
51 patients with haematologic disorders at high risk for IFD who were treated at Mie University
Hospital, Japan. Median age in years (range) 57.5 (17 to 78). Sex (male/female) 37/14
Index tests Pan-fungal PCR assay on 273 specimens
Target condition and reference
standard(s)
Revised criteria of the EORTC/MSG
Flow and timing The study was conducted between April 2007 and October 2010. 273 consecutive blood samples
from 64 risk episodes in 51 patients with haematologic disorders were analysed
Comparative
Notes IFD was documented in 14 episodes (21.9%, 9 probable IFDs and 5 possible IFDs). PCR was
positive in all of these 14 episodes, and in 4 of the 50 episodes with no IFD category. In this study,
a considerable number of fungi (44.4%) other than major ones such as Aspergillus and Candida
species were positive by PCR. Non-major fungi identified were Cunninghamella species, Fusarium
species, Scedosporium apiospermum,Rhodotorula species, Rhizopus species, Paecilomyces lilacinus, and
Penicillium sclerotiorum.
In 10 of the 18 PCR-positive episodes, continued PCR screenings disclosed the clearance of the
fungal DNA during antifungal therapy. The study also evaluated the diagnostic performance of
GM, but GM was also part of the reference standard
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Sugawara 2013 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Low
von Lilienfeld-Toal 2009
Study characteristics
Patient sampling 70 patients with febrile neutropenia (median leucocyte count 420/mm³) after chemotherapy
Patient characteristics and set-
ting
Patients treated between September 2001 and February 2002 and between April 2003 and January
2004 on the Haematology ward of the University Hospital Bonn, Germany. Median age in years
(IQR) was 60 (49 to 66). Nunber of males (%) was 38 (54)
Index tests Commercial PCR-based kit to detect the DNA of 20 different pathogens (SeptiFast), including
IFD. PCR testing was performed retrospectively
Target condition and reference
standard(s)
IFD according to the standards of the EORTC/MSG
Flow and timing 784 serum samples of 119 febrile neutropenic episodes in 70 patients with haematological malig-
nancies were analysed
Comparative
Notes The only patient with proven IFD (Candida glabrata in 1 blood culture which also grew Klebsiella
pneumoniae and Enterococcus faecium) yielded a negative result for fungus in the PCR, although the
PCR did detect Enterococcus faecium. All of the patients with probable IFDs had positive results for
Aspergillus in the PCR
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests
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von Lilienfeld-Toal 2009 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
White 2006
Study characteristics
Patient sampling A group of patients at risk of IA
Patient characteristics and set-
ting
A group of 203 patients at risk of IFD were tested by RT-PCR over a 13-month period (November
2003 to December 2004). The majority (176) were haematology patients, with 133 receiving
remission-induction therapy for acute leukaemia (68 patients) or undergoing SCT (65 patients).
The mean age of patients was 48 years
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White 2006 (Continued)
Index tests RT-PCR
Target condition and reference
standard(s)
IA. The EORTC-MSG criteria
Flow and timing Patients at risk of IFD were tested by RT-PCR over a 13-month period (November 2003 to De-
cember 2004)
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
Unclear
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White 2006 (Continued)
interpreted without knowledge
of the results of the index tests?
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
BAL: broncho-alveolar lavage
EDTA: ethylenediaminetetraacetic acid
EORTC/MSG: European Organisation for Research and Treatment of Cancer/Mycoses Study Group
GM: galactomannan
HRCT: high-resolution computed tomography
IA: invasive aspergillosis
IFD: invasive fungal disease
ITS: internal transcribed spacer
PCR: polymerase chain reaction
ELISA: enzyme-linked immunosorbent assay
RCLB: red cell lysis buffer
RT-PCR: real time polymerase chain reaction
SCT: stem cell transplant
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adhurti 2011 no 2x2 data provided
Aguado 2015 no 2x2 data available. a RCT of PCR +GM vs GM only as a screening for directing further diagnostic
strategy in pts at risk of IA
Armenian 2009 no 2x2 data provided
Auberger 2011 Retrospective study
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(Continued)
Badiee 2008 no 2x2 data provided
Badiee 2009 no 2x2 data provided
Badiee 2016a subset of patients included in another report
Badiee 2016b not invasive aspergillosis, but fungal rhinosinusitis
Bernal-Martinez 2011 only sensitivity data provided
Blennow 2010 no 2x2 data provided
Boch 2015 retrospective evaluation of a non-consecutive cohort of patients
Bolehovska 2006 Include several materials and at risk patients (not only haematologic)
Bretagne 1998 retrospective selection of patients at risk of IA from a cohort of haematologic patients
Bu Rong 2005 Case control, not consecutive pts
Bucheidt 2001 case control (control group healthy control)
Bucheidt 2004 no 2x2 data provided
Capoor 2017 case-control
Cesaro 2008 no 2x2 data provided
Challier 2004 retrospective selection
Chryssanthou 1999 Candida PCR
da Silva 2014 results of PCR and GM not available according to reference standard
Danylo 2014 Index test only in a subset of stored samples
Drogari-Apiranthitou 2016 PCR on tissue
Du 2016 case control
Gupta 2017 there was no identification to genus level so we could not identify positive aspergillus PCR results
Hadrich 2011 case control
Halliday 2005 Methodological, assay procedure
Hasseine 2010 no 2x2 data provided (published only as abstract)
79Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Hebart 2000 no 2x2 data provided
Hummel 2010 no 2x2 data provided; preliminary selection of patients
Idelevich 2015 not EORTC/MSG criteria as reference standard
Johnson 2012 gold standard different from EORTC; 3 cases only
Jones 1998 BAL only
Jordanides 2005 doesn’t distinguish Aspergillus from Candida
Kalkank 2010 no 2x2 data provided (published only as abstract)
Kami 2001 This study has combined patient samples fromboth a non-random sampling strategy and fromprospec-
tive sampling. The authors suggest a case-control approach. The study does not follow EORTC/MSG
criteria for defining IA
Kawazu 2004 no 2x2 data provided
Khalid 2017 test development, not diagnostic study
Klingspor 2006 only sensitivity data provided
Lass-Florl 2001 only sensitivity data provided
Lehrnbecher 2016 review
Li 2013 case-control
Liu 2005 Chinese
MacEsic 2017 cost-effectivness study
Mandhanija 2010 terms not according EORTC criteria (e.g., suspected cases)
Millon 2011 case control (retrospective selection of patients GM-posiitive from a cohort of haematologic patients)
Morrissey 2013 no 2x2 data available. a RCT comparing standard diagnostic strategy vs rapid biomarkers diagnostic
strategy (PCR +GM) for directing the use of antifungal agents
Nakamura 2010 PCR for bacteria and fungi, one positive case
Oz 2016 duplicate
Paholcseck 2015 retrospective evaluation of a cohort of non-consecutive patients
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Paolucci 2013 not EORTC/MSG criteria as reference standard
Reinwald 2014 retrospective evaluations of patients
Scotter 2005 retrospective, case control
Skladny 1999 retrospective, case control
Sonmez 2015 not 2x2 data available according to reference standard (EORTC/MSG criteria)
Springer 2013 retrospective, case control
Sun 2010 Chinese
Tang 2016 retrospective evaluation in a selected population of patients
Teifoori 2011 No reference standard; no 2x2 tables; not clear if pts were consecutive and when PCR was performed
White 2013 retrospective serum testing for Beta-Glucan, LFD and PCR
Yoo 2005 NASBA
Zhang 2016 case control
Zhao 2016 case control
81Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 PCR: single positive requirement 28 4989
2 PCR: two positive requirement 9 2151
3 no anti-mould prophylaxis 13 1464
4 antimould prophylaxis 12 1478
5 in-house qPCR 15 2661
6 qPCR kit 3 302
7 PCR on whole blood 15 2217
8 PCR on serum 13 2481
82Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L T A B L E S
Table1. EuropeanOrganisation forResearch andTreatment ofCancer/Mycoses StudyGroupdefinitions of invasive aspergillosis
Original definitions of Ascioglou 2002 Revised definitions of De Pauw 2008
PROVEN IA Specimen obtained by needle aspiration or biopsy from a normally sterile and clinically or radiologically abnormal
site consistent with an infectious disease processand
either histopathological, cytopathological, or direct microscopic examination of the specimen in which hyphae
are seen accompanied by evidence of associated tissue damage
or
recovery of Aspergillus species by culture from the specimen obtained by a sterile procedure excluding bronchoalve-
olar lavage, cranial sinus cavity, and urine
PROBABLE IA At least 1 host factor criterion plus 1 major (or 2 mi-
nor) clinical criteria from abnormal site consistent with
infectionplus 1 microbiological criterion
At least 1 host factor plus 1 clinical feature plus 1 mi-
crobiological criterion
POSSIBLE IA At least 1 host factor criterion plus
either 1 major (or 2 minor) clinical criterion from ab-
normal site consistent with infection or 1 microbiolog-
ical criterion
At least 1 host factor plus 1 clinical feature
Host factor criteria will include the temporal relationship between the onset of fungal disease and the receipt of an allogeneic stem cell
transplant.
Clinical features include for example neutropenia, persistent fever, predisposing conditions, prolonged use of corticosteroids; in the
case of lower respiratory tract infection, the presence of 1 of the following signs on CT: dense well circumscribed lesions(s) with or
without a halo sign or an air crescent sign, cavity.
Microbiological criteria consist of a positive culture including the presence of fungal elements indicating a mould on microscopy or
recovery by culture of Aspergillus species from sputum, bronchoalveolar lavage (BAL) fluid, bronchial brush or sinus aspirate samples;
positive result for Aspergillus detection of galactomannan antigen in specimens of plasma, serum, BAL, cerebrospinal fluid or 2 or
more blood samples. Major clinical criteria are, for example, new infiltrates on computerized tomography imaging (e.g. halo sign) or
suggestive radiological findings.
Minor clinical criteria are suggestive symptoms and signs.
The exact definitions of the European Organisation for Research and Treatment of Cancer/Mycoses Study Group criteria and their
host factor, microbiological or clinical criteria can be found in Ascioglou 2002 and De Pauw 2008.
Table 2. Technical details of the PCR methods used in the studies analysed in this review
Study Sam-
ple
type
Sam-
ple
vol-
ume
DNA extrac-
tion methodsA
PCR
method
C
Tar-
get
gene
Appropriate controls Re-
quire-
ments
for
posi-
tive by
PCR
Meth-
ods
used
(refs)
Cell
wall
dis-
rup-
tionB
DNA
isola-
tion
kit/
pro-
tocol
NegativeD PositiveE PCR
inhi-
bition
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Table 2. Technical details of the PCR methods used in the studies analysed in this review (Continued)
Ex PCR Ex PCR
Hebart
2000a
Whole
blood
5 ml Zy-
mo-
lase
and
NaOH
lysis
buffer
Pro-
tein
pre-
cipita-
tion
and
DNA
pre-
cipita-
tion
PCR-
slot
blot
18S - Yes - Yes Yes Single
posi-
tive
Ein-
sele
1997
Ferns
2002 Whole
blood
2 ml Lyti-
case
QI-
Aamp Nested
PCR
mtDNA
Yes Yes Yes Yes - Posi-
tive on
2 occa-
sions
Bre-
tagne
1998
Tang
1993
Flo-
rent
2006
Serum 200
µl
- QI-
Aamp
PCR-
ELISA mtDNA
- Yes - Yes Yes 2 con-
secu-
tive
posi-
tives
Bre-
tagne
1998
Halli-
day
2006
Whole
blood
500
µl
Lyti-
case GenE-
lute
Nested
PCR
18S Yes Yes - Yes Yes 2 con-
secu-
tive
posi-
tives
Skladny
1999
El
Ma-
hallawy
2006
Serum - Lyti-
case
QI-
Aamp
Stan-
dard
PCR
18S - Yes - Yes - Single
posi-
tive
Williamson
2000
White
2006 Whole
blood
2 ml Glass
beads MagNA
Pure
Nested
qPCR
28S Yes Yes Yes Yes Yes Serial
posi-
tives in
single
episode
Loef-
fler
2002;
Williamson
2000
Suarez
2008
Serum 1 ml
or 200
µl
-
MagNA
Pure
qPCR 28S - Yes - Yes - Single
posi-
tive
Chal-
lier
2004
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Table 2. Technical details of the PCR methods used in the studies analysed in this review (Continued)
Hum-
mel
2009
Blood 5 ml Lyti-
case
Phe-
nol-
chlo-
ro-
form
Nested
PCR
18S - Yes - Yes - Single
posi-
tive
Skladny
1999
Ramírez
2009
Whole
blood
5 ml Lyti-
case
and
glass
beads
QI-
Aamp
qPCR 18S - Yes - Yes - Single
posi-
tive
Loef-
fler
2000
Barnes
2009
Whole
blood
2 ml Glass
beads MagNA
Pure
Nested
qPCR
28S Yes Yes Yes Yes Yes Con-
firmed
posi-
tiveF
White
2006
Cuenca-
Es-
trella
2009
Whole
blood
and
serum
- - QI-
Aamp
qPCR ITS1 - Yes - Yes Yes 2 con-
secu-
tive
posi-
tives
Yoo
2008
von
Lilien-
feld-
Toal
2009
Whole
blood
10 ml Ce-
ramic
beads
Septi-
fast
qPCR 18S - Yes - Yes Yes -
Lehmann
2008
Landlinger
2010
Whole
blood
3 ml Lyti-
case MagNA
Pure
qPCR 28S - Yes - Yes Yes Single
posi-
tive
Baskova
2007;
Watzinger
2004
Badiee
2010
Whole
blood
3 to 5
ml
Lyti-
case
QI-
Aamp
qPCR 18S Yes Yes - Yes - Single
posi-
tive
Van
Burik
1998;
Kami
2001;
da
Silva
2010
Serum 5 ml
Blood
Lyti-
case
Pro-
tein
pre-
cipita-
tion
and
DNA
pre-
Stan-
dard
PCR
18S - Yes - Yes - 2 con-
secu-
tive
posi-
tives
Ribeiro
2006;
Van
Burik
1998
85Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Technical details of the PCR methods used in the studies analysed in this review (Continued)
cipita-
tion
Springer
2011
G
Whole
blood
3 ml Glass
beads
High
Pure
PCR
Tem-
plate
Prepa-
ration
Kit
(Roche)
qPCR ITS - Yes - Yes - Single
posi-
tiveH
-
Fast-
Prep-
24
MP
(Biomed-
icals)
Whole
blood
5 ml Glass
beads
Stan-
dard
PCR
- - Yes Yes Yes Yes - Sachse
2009
Rogers
2013
G
Whole
blood
3 ml Glass
beads
High
Pure
PCR
Tem-
plate
Prepa-
ration
Kit
(Roche)
Nested
qPCR
28S Yes Yes Yes Yes Yes Single
posi-
tiveI
White
2006
Springer
2011
qPCR ITS1 Yes Yes Single
posi-
tiveI
Sug-
awara
2013
Whole
blood
1 ml Beads
and
lysis
buffer
Phe-
nol-
chlo-
ro-
form
Nested
PCR
and
se-
quenc-
ing
18S - Yes - Yes - Single
posi-
tive
Naka-
mura
2010
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Table 2. Technical details of the PCR methods used in the studies analysed in this review (Continued)
Barnes
2013
Whole
blood
3ml Glass
beads
Var-
ious
auto-
mated
ex-
trac-
tors -
Roche
MagNA
Pure
LC
Total
NA,
BioMerieux
Easy-
Mag,
Qia-
gen
EZ1
Ad-
vance
XL
tissue
kit
qPCR
and
nested
qPCR
28S Yes Yes Yes Yes Yes Sin-
gle and
multi-
ple
posi-
tive
thresh-
olds
used
White
2006
Schwarzinger
2013
Serum 1 ml Not
re-
quired
Roche
MagNA
Pure
LC
DNA
qPCR Mito-
chon-
rial
- Yes - Yes Yes Single
posi-
tive
Bot-
terel
2008
Aslan
2015
Serum 0.2 ml Not
re-
quired
Qi-
amp
DNA
Mini
Kit
qPCR 18S
and
28S
Yes Yes Yes Yes Yes Single
posi-
tive
My-
cassay
As-
pergillus
and
in-
house
PCR
Bel-
langer
2015
Serum 1 ml - Large
Vol-
ume
MagNa
Pure
Nu-
cleic
acid
isola-
qPCR 18S
Mito-
chon-
drial
(L37095)
- - - - -
(no
info on
con-
trols)
Single
posi-
tive
Millon
2011,
Costa
2001
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Table 2. Technical details of the PCR methods used in the studies analysed in this review (Continued)
tion
kit
Pini
2015
Serum 0.5 ml Not
re-
quired
High
Pure
tem-
plate
(Roche)
qPCR 18S - Yes - Yes Yes Single
Posi-
tive
My-
cassay
As-
pergillus
Boch
2016 Whole
blood
3 to 5
ml
Lyti-
case
Phe-
nol-
chlo-
ro-
form
Nested
PCR
18S - Yes - Yes - Single
posi-
tive
Skladny
1999
Boluk
2016
Serum - - ZR
Fun-
gal/
Bacte-
rial
DNA
MiniPrep
Kit
qPCR Kit
(Way2
Gene
Fungi)
- Yes - - Yes Single
Posi-
tive
No ref
to
meth-
ods for
Asp
PCR
Im-
bert
2016
Serum 1 ml -
MagNA
Pure
Com-
pact
large
vol-
ume
kit
on a
MagNA
Pure
device
(Roche)
qPCR 28S - - Yes Yes Yes Single
Posi-
tive
Suarez
2008,
Chal-
lier
2004
Springer
2016
Serum 1 ml - Qi-
aamp
Ultra-
sensVirus
Kit
qPCR ITS1-
5.8S
Yes Yes Yes,
but
Bacil-
lus-
DNA
was
used
Yes Yes Sin-
gle and
multi-
ple
posi-
tive
thresh-
olds
used
Skladny
1999,
Springer
2012
88Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Technical details of the PCR methods used in the studies analysed in this review (Continued)
Badiee
2017
Serum 0.2 ml - Qi-
aAmp
Mini
qPCR 18S - - - - - -
Skladny
1999;
Shin
1999
Loef-
fler
2017
Cell-
free
blood
frac-
tion,
mostly
serum
1 ml - Qi-
aamp
Ultra-
sensVirus
Kit
qPCR ITS1-
5.8S
Yes Yes Yes,
but
Bacil-
lus-
DNA
was
used
Yes Yes Single
posi-
tive
Skladny
1999;
Springer
2016
-: not reported; MagNA Pure: an automated DNA isolation system manufactured by Roche; mtDNA: mitochondrial DNA; PCR:
polymerase chain reaction; QIAamp: QIAamp DNA isolation kit manufactured by Qiagen; Ex: extraction; ITS: Internal Trascribed
Spacer; RCLB: red cell lysis buffer.
A DNA isolation protocols may include steps to remove red and white blood cells, fungal cell wall disruption and DNA purification
kits.
B Lyticase/Zymolase enzymatically digest fungal cells walls; ceramic or glass beads cause mechanical disruption of the cell wall.
C PCR methods used vary between standard PCR where products are resolved on agarose gels to detect positive or negative reactions
or quantitative PCR (qPCR) which allows real time monitoring of the reaction. Nested qPCR involves first round standard PCR and
second round qPCR.
D Negative DNA extraction controls feature a sample blank, e.g. blood or sterile solution, that allows detection of any contamination
in the DNA isolation protocol.
E Positive DNA extraction controls are a sample blank that is spiked with fungal or specific bacterial spores to ensure that the DNA
isolation protocol is working optimally.
F The confirmed positive requires that any single positive sample is confirmed with an additional sample from the same patient. Barnes
2009 also used multiple analyses to determine the effectiveness of single versus multiple positives to yield diagnostic accuracy.
G Studies assessed the effectiveness of more than 1 assay.
H The study analysed the effect of both single and multiple positives.
I The effects of both single and multiple positives were analysed as well as analyses of combined PCR and galactomannan tests.
Table 3. Subgroup analyses
Covariate Subgroup Index mean 95% CI Subgroup Difference: P
Anti-mould
prophylaxis
yes sensitivity 0.8206 0.7536; 0.8725 not significant
no sensitivity 0.7577 0.6440; 0.8439
yes specificity 0.6470 0.5638; 0.7222 0.0387
no specificity 0.7901 0.6769; 0.8712
EORTC criteria
2008 vs 2002
2008 sensitivity 0.7311 0.6324; 0.8112 not significant
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Table 3. Subgroup analyses (Continued)
2002 sensitivity 0.7878 0.7061; 0.8516
2008 specificity 0.7339 0.6098; 0.8296 not significant
2002 specificity 0.8226 0.6559; 0.9186
Blind reference yes sensitivity 0.7384 0.6124; 0.8345 not significant
no sensitivity 0.7676 0.6652; 0.8460
yes specificity 0.6284 0.5429; 0.7065 0.0009
no specificity 0.8553 0.7555; 0.9187
Blind index yes sensitivity 0.7209 0.6402; 0.7895 not significant
no sensitivity 0.7584 0.6476; 0.8428
yes specificity 0.6646 0.5532; 0.7603 0.0161
no specificity 0.8295 0.7354; 0.8950
In-house vs com-
mercial kit
In-house sensitivity 0.7489 0.6038; 0.8537 not significant
kit sensitivity 0.6576 0.3274; 0.8835
In-house specificity 0.8428 0.7263; 0.9155 not significant
kit specificity 0.7674 0.4165; 0.9384
Whole blood vs
serum
WB sensitivity 0.8114 0.7304; 0.8724 not significant
serum sensitivity 0.7130 0.5956; 0.8073
WB specificity 0.7243 0.6382; 0.7965 not significant
serum specificity 0.8139 0.6661; 0.9056
Effects of 6 binary covariates on the sensitivity and specificity of the Aspergillus PCR. Meta-analytical pooling for proportions (method
of logits, DerSimonian-Laird estimator for tau², inverse variance method), subgroup analysis. Mean values and 95% confidence
intervals are reported. “Subgroup Difference: P” reports the comparison between 2 subgroups as difference within the same index for
each covariate, as P value. Significant results were found for specificity under prophylaxis (as decrease under prophylaxis), specificity
under blind reference (as decrease under blind reference), specificity under blind index (as decrease under blind index). Analysis
performed with R version 3.5.3.
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